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ABSTRACT
Background. Neutrophils and nitric oxide (NO) derived from inducible NO synthase (iNOS)
contributes importantly to the pathophysiology of acute lung injury (ALI) and pulmonary
microvascular endothelial cell (PMVEC) injury. However, the mechanism of neutrophil and
neutrophil iNOS dependent PMVEC injury has not been addressed. In our studies, we assessed
PMVEC activation under septic conditions, and defined the role of PMVEC vs. bone-marrow
polymorphonuclear leukocytes (PMN) iNOS in this septic PMVEC activation.
Methods and Results. We isolated PMVEC from iNOS+/+ and iNOS-/- mice lungs magnetically
by microbeads attached to anti-PECAM antibodies, sorted by flow cytometry (FACS) by DiIacetylated low density lipoprotein (Dil-Ac-LDL) uptake by cells. Bone-marrow PMNs were
isolated from femurs and tibia of iNOS+/+ and iNOS-/- mice followed by percoll gradient
isolation. Cultured PMVEC monolayers showed that basal E-selectin expression was
significantly lower in iNOS-/- vs iNOS+/+ PMVEC (MFI 16±2 vs 59±7, p<0.05). After
lipopolysaccharide (LPS) stimulation, E-selectin expression in iNOS+/+ PMVEC increased at 1
hr (MFI 146±15, p<0.01), peaked at 2 hrs (MFI 284±38, p<0.01), and then gradually declined
over 12 hrs. iNOS-/- PMVEC had a similar response to iNOS+/+ PMVEC in the timing and
magnitude of E-selectin upregulation, with a similar peak expression (MFI 257±29, p=NS vs
iNOS+/+). PMVEC responded to cytomix similarly to LPS, with PMVEC E-selectin
upregulation in a time dependent and dose dependent manner which was similar in iNOS+/+ and
iNOS-/- PMVEC. As compared to E-selectin, basal plasminogen activation inhibitor (PAI)-1
expression was similar in iNOS+/+ and iNOS-/- PMVEC. LPS-induced upregulation of PAI-1 in
ii

iNOS+/+ PMVEC peaked at 4 hrs (MFI 3.4±0.1 vs 1.7±0.1 for control medium, p<0.01), and
was sustained until 12 hrs and this pattern of LPS-stimulated PAI-1 expression was similar in
iNOS-/- PMVEC. In contrast, cytomix induced PAI-1 in iNOS+/+ PMVEC peaked at 2 hrs and
was sustained until 8 hrs, and was similar in iNOS-/- PMVEC. The presence of PMN with
PMVEC synergistically enhanced LPS induced PMVEC E-selectin expression in a dose
dependent manner. However, this LPS-induced PMN-dependent PMVEC E-selectin induction
was independent of PMN iNOS. The presence of either iNOS+/+ or iNOS-/- PMN with PMVEC
did not upregulate PMVEC E-selectin post cytomix stimulation. Moreover, iNOS+/+ or iNOS-/PMN did not affect PMVEC PAI-1 protein expression or mRNA expression after either LPS or
cytomix treatment.
Conclusions. PMVEC are activated under different septic conditions (both LPS and cytomix) as
reflected by increased E-selectin and PAI-1 expression. However, PMVEC iNOS did not affect
LPS or cytomix induced PMVEC activation.

PMN enhanced septic PMVEC E-selectin

expression following LPS treatment, and this endothelial activation was independent of PMN
iNOS. These data suggest that septic PMVEC activation in isolation or in the presence of PMN,
is independent of both PMVEC and PMN iNOS.

Keywords: Acute lung injury; sepsis; nitric oxide; iNOS; PMVEC; edema; E-selectin; PAI-1;
PMN; LPS; cytomix
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CHAPTER 1: INTRODUCTION
SECTION A
A. SEPSIS
A.1 Definition and Clinical features
In 1992 the American College of Chest Physicians (ACCP) and the Society of Critical
Care Medicine (SCCM) defined systemic inflammatory response syndrome (SIRS) as
•

Body temperature less than 36°C or greater than 38°C

•

Heart rate greater than 90 beats per minute

•

Tachypnea with greater than 20 breaths per minute; or, an arterial partial pressure of
carbon dioxide less than 4.3 kPa (32 mmHg)

•

White blood cell count less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000
cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils
(band forms)

•

SIRS can be diagnosed when two or more of these criteria are present
Sepsis is defined as SIRS due to infection (1). Sepsis can progress to severe sepsis, which

is defined as sepsis including organ failure and hypotension or hypoperfusion. Severe sepsis can
progress to septic shock which is characterized by persistent hypotension [systolic blood pressure
(BP) < 90mmHg or Mean arterial pressure (MAP) < 65mmHg], acute circulatory failure and
hypotension despite adequate fluid resuscitation (2). Other clinical features also include
hypoxemia, hyperglycemia, hyperbilirubenemia, elevated serum lactate levels (hyperlactatemia),
oliguria, and uremia, coagulopathy, thrombocytopenia, altered gastrointestinal (GI) motility

(Ileus, intestinal distention) and altered mental status due to uremic or hepatic encephalopathy (3;
4).

A.2 Epidemiology
Sepsis, which is a leading cause of death among intensive care unit (ICU) patients and
tenth leading cause of death in USA, affects 750,000 patients and causes 200,000 deaths each
year (5). The incidence of sepsis is 50 – 95 cases per 100,000 of population and are increasing by
9% each year in USA (6). According to epidemiological study in 2001, one third of patient with
SIRS have sepsis and sepsis may occur in 25% of ICU patients, 50% of septic patients proceed to
severe sepsis and 25% of patients with severe sepsis developed septic shock. The mortality rates
for sepsis, severe sepsis and septic shock have been reported as 20%, 20-40% and 30-70%
respectively (7; 8).
A.3 Pathophysiology of Sepsis
A.3.1 Sources of Sepsis

Sepsis is caused by many factors (9). Sepsis occurs due to gram negative bacteria, gram
positive bacteria, fungi and viruses (10; 10-12). For sepsis to occur bacterial inoculum must
breach to overwhelm host defence. Sepsis due to gram positive bacteria such as staphylococci
originates from skin and enterococci originate from GI tract whereas gram negative bacteria
originate from GI and genitourinary tract (13; 14). Other sources of sepsis are respiratory, skin
and soft tissue, impaired splenic function, community acquired methicillin resistant
staphylococcus aureus (MRSA), clostridial myonecrosis, bones and joints and central venous
2

catheter through intravenous (IV) infusion (15-20). Therefore, inappropriate use of antibiotics,
presence of pulmonary, intra-abdominal infections, neutropenia or multiple organ dysfunction
are also associated with increased mortality during sepsis (9).
A.3.2 Pathophysiology

During sepsis inflammatory cells are activated such as macrophages and release tumor
necrosis factor alpha (TNFα), interleukin (IL-1β), 2, 6, 11, interferon gamma (IFNγ) that act on
hypothalamus for fever, tachycardia, tachypnea (21-23). Moreover, endothelial cells (EC)
participate in inflammatory cascade by becoming adhesive to leukocytes, procoagulant and cause
barrier dysfunction and release NO and therefore alter vascular tone that results in vasodilation.
(24). Therefore, microbial pathogens, immune response, inflammatory and coagulation cascade
interactions contribute to pathophysiology of sepsis. Gram positive sepsis is initiated when cells
interact with bacterial cell wall components peptidoglycans or lipotechoic acids (LTA) activate
cells through cluster of differentiation (CD14), Toll like receptor-2 (TLR2) and may be TLR6 or
through CD14 and TLR4. Gram negative sepsis is initiated when cell recognizes
lipopolysaccharide (LPS) by lipopolysaccharide – lipopolysaccharide binding protein complex
(LPS-LBP), CD14 and TLR 4. (25).
A.3.3 Role of LPS in sepsis

LPS, a bacterial cell wall component consists of three domains, lipid A, oligosaccharide
and O antigen polysaccharide. Lipid A domain is active during human infection whereas
oligosaccharide chain determines whether LPS is smooth or rough (26; 27). LPS exists as a free
3

form or bacterial protein bound form LBP (LPS binding protein). LPS binds to LBP to form LPS
–LBP complex which then binds to cell surface receptor CD14 which is present on various
inflammatory cells. CD14 also exists as a free soluble state that is detached from membrane
bound CD14 (28). This complex then binds to cell surfaces of those cells that lack CD14
receptor like endothelial, some epithelial cells and thus initiates activation by releasing
cytokines, NO, ROS and procoagulant factors (29; 30). In humans, intravenous low dose of LPS
(2ng/kg iv) is sufficient to induce systemic inflammation and sepsis (31). However, intravenous
high dose (1 mg/kg) was sufficient to develop septic shock syndrome in human patient to treat
cancer that includes all parameters like increased cardiac output due to hypotension,
coagulopathy, thrombocytopenia, hepatic and renal dysfunction and non-cardiogenic pulmonary
edema (32).
A.3.4 Role of soluble inflammatory mediators in sepsis

Host response to sepsis can result either in eradication of microbes or it can result in
detrimental outcome (33). Therefore, the interaction of invaded pathogens and host response
triggers the release of inflammatory mediators such as cytokines, chemokines, and lipid
mediators such as prostaglandins, leukotrienes, PAF and oxidized phospholipids. Other proteases
and enzymes such as cyclooxygenase-2 (COX-2), 5-lipoxygenase, phospholipase A2,
metalloproteinase 9, elastase, inducible nitric oxide synthase (iNOS), nicotinamide adenine
dinucleotide phosphate (NADPH), mast cell dipeptidyl peptidase 1, glycogen synthase kinase-3
also contributed to initiation of inflammatory responses. It has been documented that cell marker
of stress high mobility group box 1 protein (HMGB1), vasoactive substances such as histamine
4

and serotonin, plasma factors Ligand of Triggering receptor expressed on myeloid cells-1
(TREM-1), Anaphylatoxin C5A, Mannose binding lectin (MBL), neuromediators

such as

substance P, neurokinin and noredrenalin plays a major role in sepsis. Furthermore, coagulation
factors such as tissue factor (TF), plasminogen activating inhibitor (PAI-1), thrombin, thrombin
activable fibrinolysis inhibitor (TAFI), free radicals such as nitric oxide (NO) and superoxide
(O2-) and purine nucleoside (Adenosine via A2A receptor) by inflammatory cells are involved in
sepsis. (34-37).
Glycoproteins or cytokines are produced by leukocytes and work in an autocrine,
paracrine or endocrine manner (35; 38). During early sepsis, several studies have identified that
various pro-inflammatory cytokines [IL-6, IL-8, IL-12, IL-17, INF-γ, TNF, IL-1 , keratinocyte
chemoattractant (KC), macrophage inflammatory protein-2 (MIP-2), monocyte chemoattractant
protein-1 (MCP-1), granulocyte colony stimulating factor (GC-SF)] in animal and human plasma
are associated with mortality (6; 39; 40). Moreover, anti-inflammatory serum cytokine (TNF
soluble receptors, IL-10, IL-1 receptor antagonist) levels are also higher in human patients who
do not survive (6; 39; 41). During onset of sepsis, this “cytokine storm” results in activation and
influx of neutrophils, as well as activation of many other cells, including macrophage/monocyte,
epithelial cells, EC, and natural killer (NK) cells; all of which results in production of reactive
oxygen species and reactive nitrogen species that are detrimental in sepsis (6; 6; 42-45).
A.3.5 Neutrophils
Normal Physiology
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Neutrophils are generated in bone marrow through a process of granulopoiesis in the
presence of granulocyte colony stimulating factor (G-CSF) (46). Neutrophils are short-lived cells
and are removed by apoptosis by resident tissue macrophages in liver, spleen and bone marrow.
The half-life of neutrophils is 6-10 hrs post migration from bone marrow (47). During sepsis,
neutrophils are transmigrated to the site of infection/injury. Normally, they express cell surface
receptors that are useful markers for differentiating different stages during cell development (48).
For example CD34 expressed on early precursor cells, CD11/18 β2 integrins are expressed late
during development (49). It has 3 isoforms. CD11a/CD18 and CD11c/CD18 are involved in
adhesion and migration whereas CD11b/CD18 is involved in cellular adhesion (50; 51). In lung,
transendothelial migration of neutrophils can be either CD18 dependent and independent,
depending on the inflammatory stimulus (52).
Neutrophils in Sepsis
Activated neutrophils transmigrate into lung tissue across the endothelium during sepsis
or initiation of inflammatory cascade (53). Activated neutrophils undergo cytoskeletal
derangements and deform to pass through capillary network (54). Transmigration occurs in 3
steps, capturing and rolling on endothelium, adhesion and transmigration through pores due to
junctional proteins disruption. Ligation of L-selectin on neutrophil to CD34 on endothelium
facilitates rolling. L-selectin is induced for few minutes thus, ligation of P-selectin on
endothelium to PSGL-1 on neutrophils accomplishes slowing and rolling of neutrophils on
endothelium. Ligation of E-selectin on endothelium to ESL-1 on neutrophil facilitates adhesion.
Firm adhesion is accomplished when neutrophils Mac-1 (CD11b/CD18) ligates with ICAM-1 on
endothelium and neutrophils β1 integrins very late antigens (VLA-4 and VLA-5) ligates with
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VCAM-1 (55-57). Finally migration occurs when PECAM-1 on neutrophils ligate with PECAM1 on endothelium in some model of sepsis however, some reported JAM-1 contributed in
neutrophil trans-endothelial migration during inflammation and sepsis (58; 59). Moreover,
ICAM-2, JAM-A, and PECAM-1 also contributes to neutrophil migration through venular walls
in vivo (60).
PMN activation, migration and sequestration contribute to the development of sepsis
(57). There is release of degradative enzymes (elastase and cathepsin G), ROS and reactive
nitrogen species (RNS) produced by neutrophils in tissue injury (61-65).
Moreover, PMN neutrophil extracellular traps (NETs) formation has been important
feature of sepsis and infections. However, depletion of PMN NETs by rhDNase can worsen the
parameters of sepsis (66). The literature suggests that in neutropenic septic (PMN-/E coli)
animals, there is significant histopathologic damage in the adrenal glands and liver and large
accumulation of albumin leak in kidneys. However, multiple organ dysfunction was prominent in
neutrophil septic animals which was attenuated with PMN depletion (67). Moreover, neutrophil
depletion in chest trauma induced ALI has shown to decrease IL-1β, IL-6, bronchoalveolar
lavage protein concentration and pulmonary myeloperoxidase activity in mice (68).
Microvascular protein leak in sepsis-induced ALI is uniquely dependent on iNOS in
inflammatory cells with no obvious contribution of iNOS in pulmonary parenchymal cells (69).
Recently, we have shown that pretreatment with anti-CD18 before cecal ligation/perforation
significantly reduced pulmonary myeloperoxidase, bronchoalveolar lavage neutrophils,
microvascular EB-albumin leak, and 8-isoprostane content (70). Neutrophils are directly
involved in causing endothelial activation, barrier dysfunction by increasing permeability and
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cytoskeletal derangement during sepsis (45; 71). However, role of mice PMN iNOS in PMVEC
activation post LPS or cytomix has not been identified.
A.4 Diagnosis and Treatment of Sepsis, severe Sepsis or Septic shock
A.4.1

Diagnosis

As described above, sepsis is caused due to infection and to diagnose infection various
laboratory tests are performed. To diagnose bacteria during SIRS/sepsis, blood culture is done
and a complete blood test is also performed to evaluate erythrocytes, white blood cells (WBCs)
and platelets (72). Blood test is also performed to evaluate arterial blood gases, lactate level,
blood glucose, electrolyte imbalance and C reactive protein (73). Prothrombin time (PT) or
partial thromboplastin time (PTT) tests are performed to analyse blood clot formation duration
(74).
Urine analysis is done for presence of Escherichia coli or Klebsiella enterococci for
urinary tract infection (UTI) or gall bladder infection or bacteriodes fragilis for pelvic or colonic
infection (75; 76). If MRSA (methicillin resistant streptococcus Auresus) is diagnosed then there
is possibility of occurrence of lower respiratory tract infections or pneumonia (76; 77).
Chest X ray is done to evaluate haemorrhage, emboli, pleural effusion, cancer,
pneumonothorax, fluid overload/edema, congestive heart failure and acute myocardial infarction
(78). Abdominal ultrasound is important to diagnose any biliary tract obstruction or infection or
infection in ovaries (79). Abdominal computerized tomography (CT) scan or magnetic resonance
imaging (MRI) is important for diagnosing appendicitis or pancreatitis, nephritis or soft tissue
abscesses like in spine (73).

8

Procalcitonin levels are used as a marker to distinguish sepsis from nonseptic systemic
inflammation. Plasma concentration of soluble TREM-1 (triggering receptor expressed on
myeloid cells), a member of the immunoglobulin superfamily are increased in septic patients in
the presence of bacterial products. The clinical usefulness of Procalcitonin and TREM-1 is still
in its preliminary phase. More clinical trials are still required for clinicians to suggest routine
use.
A.4.2 Treatment
As described earlier, sepsis is due to infection. Therefore, antibiotic therapy for the
underlying infection is critical (80). Empiric antibiotic treatment is given intravenously even if a
specific bacterial infection is not diagnosed yet. The empiric treatment should be meropenem,
cefoperazone, or cefepime plus additional coverage for staphylococci (81). If MRSA is prevalent
in the hospital, then linezolid, vancomycin, or daptomycin can be given. Vancomycin should be
avoided if coagulase-negative staphylococci are detected from the blood because this is a lowvirulence organism. If intravenous lines or catheter tubes are source of infection then it should be
replaced but if cannot be replaced in patient with MRSA or coagulase negative staphylococcal
infection due to any medical or clinical reasons then vancomycin can be given. Linezolid,
daptomycin and tigecycline are almost universally active against MRSA(82).
Preferred therapy for biliary-tract infections (cholecystitis/cholangitis) due to Escherichia
coli, Klebsiella species, and Enterococcus faecalis is with imipenem, meropenem, piperacillin, or
cefoperazone. Many physicians prefer penems such as imipenem, meropenem, piperacillin
(extended spectrum penicillin)/tazobactam (beta lactamase inhibitor), or ampicillin/sulbactam to
treat intra-abdominal and pelvic infections due to gram-negative bacilli and B fragilis,
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enterococci. However, many prefer combination therapy such as clindamycin or metronidazole
plus aztreonam, levofloxacin, or an aminoglycoside for intra-abdominal and pelvic infections.
Surgical drainage is also required.
Urosepsis is mainly caused by gram-negative bacilli, such as coliforms or enterococci.
Empiric treatment for urosepsis due to gram-negative bacilli can be monobactam such as
aztreonam, floroquinolones such as levofloxacin, third- or fourth-generation cephalosporins, or
an aminoglycoside. Urosepsis due to enterococci (E faecalis) can be treated with ampicillin or
vancomycin when the patient is penicillin-allergic.
S aureus sepsis is usually associated with infection caused by devices or acute bacterial
endocarditis. Empiric antibiotic therapy can be nafcillin (beta lactamase resistant), an antistaphylococcal, cephalosporin, a carbapenem, linezolid, or clindamycin with or without rifampin.
Pneumococcal or meningococcal sepsis may be treated with penicillin G or a beta-lactam. Early
appropriate treatment of antibiotics can reduce mortality in sepsis or septic shock patients (83).

A.4.2.1Supportive (Non-Pharmacological and Pharmacological strategies)
In adults, treatment of sepsis, severe sepsis or septic shock is largely supportive.
Supplemental oxygenation or mechanical ventilation may be necessary to facilitate breathing if
SaO2 is less than 93% (84). Non-invasive ventilation may be required to support the increased
respiration that follows sepsis, for airway protection as encephalopathy and altered mental level
of consciousness complicate sepsis (85).
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If patient is in severe sepsis or septic shock [mean arterial pressure (MAP) <65 mmHg,
central venous pressure (CVP) is less than 8, urine output <0.5ml/kg/hr, central venous oxygen
saturation<70%, mixed venous oxygen saturation<65%] careful use of 20mL/Kg of saline
solution should be given within 1 hour or diuretics (furosemide, Lasix) to optimize fluid status
(86-88). It has been described that fluid resuscitation is important for Lactate clearance or to
improve central venous hemoglobin saturation (ScvO2) in septic, severe septic or septic shock
patients. In a clinical trial when septic patients had resuscitation for lactate clearance ≥10 percent
or improve ScvO2 ≥70 percent, there was no difference in hospital mortality, length of stay,
ventilator-free days, or incidence of multiple organ failure (89). Hypokalemia, hypocalcemia,
hypomagnesemia and hypophosphatemia has been manifestated due to diuretics during acute
renal failure recovery (90).
The appropriate use of crystalloids such as saline solution, ringers lactate and dextrose
and colloids such as hydroxyethyl starch and gelofusine is still under debate in septic shock (86).
If hematocrit is less than 30%, red blood cells (RBCs) should be transfused until hematocrit is
greater than 30 (87). If MAP is still less than 65 mmHg post fluid administration, vasopressors
(norepinephrine) and vasopressin should be given to increase blood pressure and provide cardiac
support (86).
Serum free cortisol (glucocorticoid) is a method to assess adrenal function during sepsis
(91). Before 1990, high dose corticosteroids have shown detrimental effects in improving sepsis
or septic shock (92). It has been stated that high dose of hydrocortisone for reversal of sepsis or
septic shock can be harmful as excess hydrocortisone can cause hyperglycemia, cushing
syndrome and adrenal suppression (93). High dose methylprednisolone has shown to reduce
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TNFα induced (HBMVEC) human brain microvascular endothelial cell ICAM-1 and VCAM-1
expressions (94).
During early 2000, low dose corticosteroids have shown benefits in improving conditions
of septic shock. The ability to show beneficial effects of cortisol in septic or septic shock patients
is still under debate. Low dose hydrocortisone had shown some beneficial effects but in a most
recent clinical trial even low dose corticosteroid administration did not reverse sepsis or septic
shock in patients (86). In 2005, low dose hydrocortisone has reversed septic shock and reduced
IL-1 and IL-6 plasma levels (95). In late 2000s low dose hydrocortisone has shown detrimental
effects in improving septic conditions or septic shock (96). In contrast, recently documented that
mild dose dexamethasone (0.25 mg/Kg) M/DEX or high dose (2.5 mg/kg) H/DEX significantly
attentuated cytokine messenger RNA expression in the lung, liver, and kidney. However, low
dose (0.05mg/kg) L/DEX could not significantly reduced plasma level cytokines but reduced
cytokine messenger RNA expression in lung, liver, and kidney tissue and reduced the occurrence
of bacteremia in mice post CLP (97). Low dose corticosteroids should be administered in septic
shock patients where fluid rescusitation or vasopressors does not work. However, more clinical
trial may be required for use of appropriate concentration and duration of low dose corticosteroid
administration in septic patients (98). As such, many practitioners in US are still reluctant to use
steroids therapy for severe septic shock as there is no survival benefit (99).
In case of organ failure in severe sepsis and septic shock, supportive measures are
provided such as dialysis for kidney failure. (86). Some studies have shown that analgesics
given during mechanical ventilation have prolonged duration of mechanical ventilation but
interrupted analgesic treatment has decreased mechanical ventilation duration (86; 100; 101).
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Glucose level should be maintained <150 mg/dL and during hyperglycemia in septic
patients IV insulin infusion should be monitored every hour initially and then every 4 hours (86).
Studies have shown reduction in mortality in Intensive care unit (ICU) patients who received
insulin infusion. Moreover, in mice post 2 hit hyperglycemic model i.e femoral fracture followed
by CLP, insulin therapy was associated with improvement in survival rates and few neutrophils
infiltrates and reduced IL-6 and IL-10 mRNA expression in lung and liver. Therefore, insulin
had a direct anti-inflammatory impact that was independent of reducing blood glucose levels
(102).
Enteral feeding eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and
antioxidants with during severe sepsis or septic shock have shown improve oxygenation, more
ventilator and ICU stay free days which is correlated with reduced mortality rate (103).
A.4.2.2Experimental Strategies
Many anti-septicemic, anti-inflammatory and anti-coagulant therapies has been tried to
improve survival (104; 105). Endotoxin neutralizing agents, bactericidal permeability increasing
protein has shown improvement in preventing morbidity but when it was tried in children with
fulminant

meningococcemia,

it

did

not

improve survival

(106;

107).

Intravenous

Immunoglobulin had been proposed as an adjuvant therapy for septic treatment but it is not
recommended by physicians as there is a need of large clinical trials to evaluate the effect of
doses and duration of this treatment (108).
Numerous clinical trials have been conducted to block inflammatory responses but still
researchers are unable to answer if mortality due to sepsis can be controlled. It has been
documented that increased dosage of endotoxin or cytokines has caused mortality (109; 110).
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Anti-TNF α therapy has increased or decreased mortality in septic patients or animals (111; 112).
In contrast, this does not reflect clinical scenario of sepsis in which people with sepsis had
detectable TNF-α (5-10 pg/ml) and IL-1β levels and septic patients treated with TNF-α blocking
agents has improved survival in some study and many have not been successful (113).
Antagonist to TNF alpha, IL-1 beta, bradykinin, cyclooxygenase and caspases also have variable
effect on survival of septic animals and in human (114-116).
Based on a presumed role of activation of coagulation pathways in sepsis, and reduced
levels of activated protein C (APC), administration of APC (drotrecogin alpha, Xigris) as an
anticoagulant, and possibly as an anti-inflammatory agent, can be beneficial in patients with
severe sepsis or septic shock who have high risk of death. APC has been shown to reduce
mortality in septic or septic shock patients but some studies have not shown any effect. (105).
Some studies reported that it has adverse effect on bleeding so it should be avoided when there is
a risk of bleeding (117). However, because of risk and lack of consistent benefit, APC was
withdrawn as a treatment for patients in 2012.
Statins [(3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (HMG-Co A reductase
inhibitors)] such as simvastatin have been used to reduce mortality in severe septic patients as
compared to patients who did not receive it (104; 116; 118). Despite of advancement in the
treatment of septic, severe septic or septic shock patients, mortality rate is still high. More
research is required into cellular pathways of sepsis, including neutrophils and endothelial cells.
There is currently no accepted therapy which targets the inflammatory aspect of sepsis, or the
injury at the cellular level.
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SECTION B
B. ACUTE LUNG INJURY/ACUTE RESPIRATORY DISTRESS SYNDROME

B.1 Definition
The definition of ALI/ARDS was initially recommended by American European consensus
conference (AECC) in 1994 has been used in many clinical trials and research. According to
Berlin criteris which has modified the features explained by AECC, diagnostic criteria for ALI
include acute onset, the presence of diffuse radiographic pulmonary opacities, severe hypoxemia
quantified by the ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired
oxygen (FiO2) less than 300 mmHg (ALI) or less than 200 mmHg (ARDS). The presence of
pulmonary edema due to cardiac disease (mitral stenosis, left ventricle failure) is diagnosed by
measuring pulmonary capillary wedge pressure (PCWP) clinically, or by measuring vascular
permeability in research setting. Pulmonary edema due to non- cardiogenic cause is diagnosed
when PCWP is less than 18 mmHg (119).
ALI/ARDS is caused by direct and indirect insult. Direct insult due to direct injury to the
lung include pneumonia, acid or gastric aspiration, toxic inhalation, drowning, fat or amniotic
fluid embolism, pulmonary contusion, alveolar haemorrhage, pleural effusion drainage,
embolectomy, unilateral lung re-implantation and trauma. Indirect insult that is associated with
sepsis, shock, blood transfusion, cardiopulmonary bypass, pancreatitis, salicylate or narcotic
overdose (119; 120). Sepsis is one of the common indirect cause of ALI and has been focus of
interest for clinicians and scientists.
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B.2 Epidemiology

In 1967, Ashbaugh and colleagues termed ARDS (acute respiratory distress syndrome) in
12 critical ill patients in ICUs suffering with acute respiratory failure, decreased lung compliance
and diffuse opacities that was evident on chest radiograph (121). Since then diagnostic criteria
has been modified (122). ALI/ARDS is one of the leading causes of death in ICUs. Some have
reported low mortality in patients that were admitted to non-ICU wards in US hospital (123). The
incidence of acute lung injury varies between studies: 17-54 cases per 100,000 people in US in 1
study in 2005 which was higher than Europe, Australia and other developed countries (124), but
another study suggested a higher incidence of 30 – 75 cases per 100,000 people in United states
each year (125). The in hospital mortality rate was 38.5 percent for ALI and 41.1 percent for
ARDS. In 2005, approximately 200,000 patients were affected annually in US with mortality rate
of 40 % (126; 126). Rubenfeld and colleagues also stated that the incidence of acute lung injury
was increased with age as they reported that 16 cases were affected per 100, 000 people with
ages between 16- 19 and 306 cases were affected per 100, 000 people with ages between 75- 88
years (126).
ARDS patients, who survived, suffered from cognitive abnormalities, depression, muscle
weakness, fatigue and post-traumatic stress (127). Mortality rate of ALI/ARDS patients has been
decreased to almost 31% due to advancements in new ventilator strategies like low tidal volume
ventilation that suggests that ALI/ARDS due to other non-hypoxemic cause like sepsis induced
multiple organ failure also contributes to this deadly syndrome (128). Many ALI/ARDS patients
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accompanied by severe sepsis or shock can cause non-pulmonary failures such as cardiovascular
failure thus requires vasopressors, renal failure thus requires dialysis, liver failure and
haematological disorders leads to anemia, thrombocytopenia (129). Thus, mortality rate of these
ALI/ARDS patients due to non-pulmonary failures is still high so etiology and pathophysiology
of ALI/ARDS has been subject of great interest by researchers.
B.3 Pathophysiology

ALI is subdivided into three different phases (130). During initial 12-72 hours of onset of
ALI, there is increased accumulation of interstitial and alveolar edema that is associated with
alveolo-cappillary membrane damage. This exudative phase which lasts for 1-7 days is
characterised by increased inflammatory cells sequestration, thrombus formation, decreased
blood flow and perfusion leads to hypoxia induced vasoconstriction, altered surfactant function
due to changes in phospholipids, fatty acid, neutral lipid, imbalanced surfactant apoprotein
composition, plasma protein interaction or any inhibitors in edema exudate, inflammation,
epithelial and endothelial injury or incorporation of surfactant phospholipids with fibrin strands
due to increased PAI-1 in alveolar compartment (131; 132; 132-135). It has been reported that
surfactant therapy has improved gas exchange and normalized surfactant phospholipid and
protein content in neonates (136). However, alveolar surface activity was significantly impaired
before surfactant treatment and only partially improved after surfactant administration.
Moreover, there was twofold increase in neutral lipid content and altered neutral lipid profile in
broncho alveolar lavage fluid in patients with ARDS compared with healthy controls or even
after large dose of surfactant administration (130; 137; 138).
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This exudative phase leads to fibro-proliferative phase which causes collagen matrix
production persists for 5-7 days of onset of ARDS. This collagen deposition leads to fibrosis,
which correlates with increased mortality in ARDS patients (135). Moreover, recently it has
been suggested that epithelial-mesenchymal transition (EMT) leads to pulmonary fibrosis (130;
137; 139).
Damage to pulmonary vasculature leads to activation of endothelial cells. Therefore,
increased levels of plasma PAI-1 and broncho-alveolar lavage PAI-1 are increased in ALI (140;
141). Over whelming inflammation is a prominent feature during exudate phase of ALI due to
over production of cytokines (IL-1β, IL-6, IL-6ra) and cellular mediators such as NF-kB and
sFasL and activated neutrophils contribute to epithelial damage and apoptosis (142; 142; 143).
B.3.1 Inflammatory cells
B.3.1.1 Neutrophils in ALI

ALI is characterized by increased protein rich edema fluid in the pulmonary interstitium
and airspaces, which suggests pulmonary micro vascular endothelium is damaged. There is
increased influx of activated neutrophils in the lung during development of ALI. Neutrophils are
the first that recruits to the site of inflammation (142; 143).
Neutrophils recruitment in the lung occurs in stages, similar to the systemic circulation.
However, rolling is not an important feature of neutrophil-PMVEC interaction in the pulmonary
circulation. Neutrophil-PMVEC adhesion can be either β2 integrin-dependent or independent in
acute lung injury, depending on the inflammatory stimulus. Adhesion can also be mediated
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through L, P and E-selectin, but firm adhesion, especially in sepsis, is usually mediated through
β2 integrin interaction with intracellular adhesion molecule (ICAM-1) and β1 (VLA-4 and VLA5) integrins which interact with vascular cell adhesion molecule (VCAM-1) on endothelium (5557). In human, deficiency of β2 integrins also called leukocyte adhesion deficiency (LAD), leads
to recurrent infections (144). Inhibition of β2 integrins has reduced neutrophil recruitment (145).
Integrin dependent firm adhesion on endothelial cells results in respiratory burst in neutrophils
that further causes damage to endothelial cells (146).
The next step is neutrophil transmigration across PMVEC in a transcellular or
paracellular manner Migration occurs when PECAM-1 on neutrophils ligate with PECAM-1 on
endothelium in some model of septic ALI. However, some have reported JAM-1 contributed to
neutrophil trans-endothelial migration during inflammation and septic ALI (58; 59). Moreover,
ICAM-2, JAM-A, and PECAM-1 also contributes to neutrophil migration through venular walls
in vivo (60). Repeat explained above
Neutrophils are directly involved in endothelial protein leak in septic animals in model of
ALI. Various studies have shown that neutrophils are involved in endothelial activation in sepsis
induced ALI models (55-57). Prevention of neutrophil activation, neutrophil adhesion and
neutropenia has attenuated edema in various animal model of septic ALI. Moreover, neutrophil
depletion in chest trauma induced ALI has proved attenuated levels of IL-1 beta, IL-6,
bronchoalveolar lavage protein concentration and lung myeloperoxidase activity in mice (68).
Microvascular protein leak in sepsis-induced ALI is dependent on iNOS in inflammatory cells
with no obvious contribution of iNOS in pulmonary parenchymal cells (69). Recently, we have
shown in model of septic ALI that pretreatment with anti-CD18 before cecal ligation/perforation
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markedly reduced septic increases in pulmonary myeloperoxidase, bronchoalveolar lavage
neutrophils, microvascular EB-albumin leak, and 8-isoprostane content (70). Neutrophils are
directly involved in endothelial activation, barrier dysfunction by increasing permeability and
cytoskeletal derangement during sepsis (45; 71);(68). This suggests important contribution of
neutrophil sequestration in edema formation during sepsis induced lung injury.
Neutrophil granules have played an important role during lung injury. Azurophilic
(primary) and specific (secondary) are released when neutrophils enter the tissue, gelatinase
(tertiary) are released during neutrophil transmigration and secretory vesicles are during
endothelial and neutrophil contact. (147; 148). Neutrophil Protease such as elastase and
cathepsin G is found in bronchoalveolar lavage fluid (BALF) and blood of ALI/ ARDS patients
(149-151). Neutrophil Cathipsin G, elastase and proteinase-3 has caused endothelial injury and
increased permeability in ALI (152; 153). Moreover, Neutrophil elastase and Cathepsin G has
reduced only gram negative infections but not gram positive (154). Neutrophils Protease
cathepsin G, elastase and proteinase 3 have shown to degrade surfactant A and D, antiinflammatory proteins and increased lung permeability and coagulation (155; 156). Neutrophil
protease elastase inhibitor, sivelestat sodium or neutrophil radical scavenger edaravone has
shown attenuation of IL-6 and TNFα in rat lungs in a model of LPS induced lung injury (157).
Neutrophils antimicrobial polypeptides lactoferrin levels are correlated with decreased
pulmonary edema, inflammatory cells infiltration and pulmonary myeloperoxidase activity in
LPS induced ALI in mice whereas, alpha defensins have detrimental effects in ALI as it is
elevated in BALF in ALI/ARDS patients and in animals that are chemoattractants for monocytes
and macrophages (158; 159).
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B.4 Treatment of ALI/ ARDS

Todate there is no exact treatment for ALI/ARDS, therefore, combination of therapies
supportive/non-pharmacological and pharmacological are being used to improve patient survival.
B.4.1 Non pharmacological Strategies
B.4.1.1 Mechanical Ventilation

The goal is to achieve PaO2 >60mmHg or arterial oxyhemoglobin saturation (SaO2)>
90% with FiO2<60% through mechanical ventilation either noninvasive (masks) or invasive
(endotracheal intubation). During early 48 hours target oxygenation should be achieved
otherwise there is a risk of oxygen toxicity which can damage lung airways, lung parenchyma,
bronchopulmonary dysplasia in neonates, retinopathy of prematurity or retrolental fibroplasias.
The main goal of mechanical ventilation is to provide adequate oxygenation, adequate alveolar
ventilation, avoid overdistension and auto-PEEP.
The most commonly used supportive and protective therapy includes techniques of
mechanical ventilation using low tidal volumes to limit end inspiratory plateau pressure
(<30cmH2O). If the plateau pressure is >30 cm of water, then tidal volume should be decreased
to 5 mL/kg or as low as 4 mL/kg if required. It has been documented that high tidal volume can
cause pneumothorax and low tidal volume can cause hypoventilation (160; 161). Moreover,
mortality is also reduced in ARDS patients who were treated with using low tidal volume (68mL/Kg) as compared to high tidal volume group. Permissive hypercapnia is an important risk
associated with low tidal volume in patients with ALI/ARDS. Hypoventilation increases PaCO2
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which results in respiratory acidosis. To treat respiratory acidosis respiratory rate should be
increased. Moreover, physicians also recommend sodium bicarbonate infusion, Carbicarb or
Tromethamine (THAM) if blood pH < 7.15.
Positive end expiratory pressure (PEEP) should be titrated according to lung compliance,
inflation pressure curve, and stress index. PEEP is titrated on mechanical ventilators according to
Vt (tidal volume) and frequency. PEEP is applied to reduce the need for supplemental oxygen i.e
FiO2≤0.6 (60%). PEEP increases mean airway pressure, improves gas distribution, reduces
atelectasis, increases functional residual capacity (FRC), minimizes pulmonary edema, reduces
shunt, improves ventilation perfusion mismatch and improves oxygenation and which allows
physicians to reduce FiO2. In addition, increased PEEP may cause alveolar overdistension and
produce ventilator associated lung injury (VALI). Moreover, PEEP may increase intrathoracic
pressure that decreases venous return and cardiac output (CO), and lowers blood pressure or
results in hypotension in patients with hypovolemia and ALI. Furthermore, impact of PEEP on
hemodynamics is still controversial. It has also been reported that high PEEP is beneficial for
ARDS patients not for ALI. Experimental studies revealed that PEEP levels greater than
traditional values of 5 to 12 cm H2O can reduce mortality cyclical alveolar collapse and shearing
pulmonary injury in patients with edema, alveolar collapse or ARDS.
Sometimes continuous positive airway pressure (CPAP) ventilation alone may be sufficient
to improve oxygenation and it has better effect on blood pressure than PEEP due to increase in
MAP with CPAP. However, in small number of patients with ARDS/ALI and in neutropenic
patients, the use of this technique has allowed some patients to avoid intubation. The overall aim
is to maintain acceptable gas exchange and to minimize adverse effects during procedure. It has
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been reported that CPAP has been used to reduce FIO2 below 65%. To find optimal or
appropriate level of CPAP in patients with ARDS is under discussion. In patients with ALI,
CPAP may reduce shear forces that accelerate ventilator-associated lung injury by keeping the
alveoli in an expanded state throughout the respiratory cycle.
Mechanical ventilated patients are also at the risk of deprived sleep, malnutrition,
hypotension, oliguria and gastrointestinal bleeding. Antacid, proton pump inhibitors or histamine
blockers (H2) are used to reduce gastrointestinal complications.
B.4.1.2 Alternative or Rescue Ventilator Modes in ARDS

To treat severe hypoxemia or hypercarbia with acidemia despite optimal treatment with
low-tidal volume mechanical ventilation in patients with severe ARDS, alternative ventilator
strategies are used.
B.4.1.3 Inverse ratio ventilation (IRV) and Airway pressure release ventilation (APRV)

Some physicians use pressure controlled ventilation strategy to manipulate the mean
airway pressure by prolonging inspiration, and this method has shown to improve oxygenation
without increasing peak or plateau pressures and it also improves gas distribution at the end of
inspiration. During hypoxemia in ARDS patients, longer Inspiratory times than expiration
(inverse I:E ratio ventilation, ratio 7:1) may be beneficial. However, patient feels discomfort and
really needs heavy sedation that can reduce this effect of auto-PEEP and hypotension.
Neuromuscular paralysis has improved ventilator-patient synchrony and often improved
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oxygenation in patients with ALI. In patients with severe ARDS (PaO2/FiO2 ratio<150), 48 hours
of neuromuscular paralysis with cisatracurium (Nimbex) has improved oxygenation and
improved mortality.
Newer pressure control modes such as Bilevel/APRV (Airway pressure release
ventilation) have been used to reduce discomfort that occurred with IRV in patients with
ALI/ARDS. APRV has attenuated airway pressures, minute ventilation and dead space
ventilation and increased spontaneous breathing and also reduced use of sedation and increased
cardiac output.
High-frequency oscillatory ventilation (HFOV) is a ventilator mode that uses low tidal
volumes and high respiratory rates. In largest randomized controlled trial, it has been found that
the HFOV group had early improvement in oxygenation that could not persist beyond 24 hours
as compared to conventional ventilation. Mortality is also reduced in HFOV group and it may be
the most useful for patients with bronchopleural fistulae (160-162).Recently, it has been
documented that HFOV is not beneficial in patient’s survival as in hospital mortality was 47% in
the presence of 6ml/kg tidal volume and adequate PEEP as compared with control which was
35%.
B.4.1.4 Liquid ventilation

Novel modes of liquid ventilation have been studied, and are occasionally used clinically.
These include perfluorocarbon (PFC) for partial liquid ventilation, perfluorohexane for PFC
Vaporization and perfluorooctance for aerosolization (163-165). Resolution of gas exchange
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impairment with liquid ventilation PFC has been beneficial in preterm neonates as compared to
PEEP that can lead to broncho pulmonary dysplasia (166). Partial liquid ventilation has also been
tried in ARDS but mortality is still higher (167). Vaporization of Perfluorohexane or
aerosolization of perflurooctane has been shown to improve gas exchange in oleic acid-induced
lung injury in sheep (168).
B.4.1.5 Prone position

It is used to open or increase surface area of atelactic lung and improve oxygenation but
still this strategy is failed in reducing mortality in ALI/ARDS patients. In contrast, in most
severe ARDS patients prone positioning has reduced mortality. It is still considered a rescue
therapy for refractory hypoxemia (169). The most common complications of prone positioning
ventilation include extubation and the development of pressure ulcer.
B.4.1.6 Extracorporeal membrane oxygenation (ECMO)

ECMO is not routinely used as a rescue therapy for ALI/ARDS but still it has been used
to treat refractory hypoxemic and severe ARDS patients to improve oxygenation (170). ECMO is
associated with complications and increased mortality in ARDS patients such as hemorrhage
(171). However, scientific evidences for ECMO in ARDS patients with life threatening
hypoxemia and VALI is also lacking. Thus, there is a need for more clinical studies.
B.4.2 Pharmacological Strategies
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Fluid Management. The most recent trial in ALI management is to restrict fluid intake specially
ARDS due to pneumonia, inhalation injury, aspiration but ARDS due to inflammation and
infection or septic shock may require initial fluid therapy to stabilize patient. In ARDS or ALI
clinical trial study of a fluid-conservative strategy versus a fluid-liberal strategy in the
management of patients with ARDS or acute lung injury (ALI) found no statistically significant
difference in 60-day mortality between the 2 groups 72 hours after presentation with ARDS
(172). Patients treated with the fluid-conservative strategy had an improved oxygenation index
and lung injury score and an increase in ventilator-free days, without an increase in
nonpulmonary organ failures. Fluid restriction strategy has reduced duration of mechanical
ventilation but has no effect on mortality in large clinical trial studies in patients with ALI who
were not in shock (173).
Diuretics are used to minimize the left ventricular filling pressure by fluid restriction.
Even if PCWP is less than 18 mmHg, reduced oncotic pressure can cause septic ALI however,
combination of Albumin and furosemide therapy has significantly improved oxygenation, net
negative fluid balance and hemodynamic stability but not mortality in ALI/ARDS patients (174).
Transfusion of packed RBCs in patients with low hematocrit, however, recently
documented that in patients with new-onset ALI, sepsis and shock, there is no correlation
between RBC transfusion and mortality or ventilator free days. This suggests RBC transfusion
has no effect on ALI patients mortality rate (175).
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Antibiotics. Evidences suggested that more than 60% ARDS patients have pulmonary infection
either before or after the onset of lung injury. Thus, appropriate antibiotic therapy must be
administered as already discussed in sepsis section (83).
Sedatives. To avoid patient ventilator synchrony that causes anxiety, sedatives are given. In
patients with severe ARDS receiving mechanical ventilation, administration of neuromuscular
blockers such as cisatracurium showed improvement in 90-day survival and increased time off
the ventilator (101; 176).
Vasopressors. In order to maintain MAP more than 70 mmHg, vasopressors and vasopressins
may be required and norepinephrine and dopamine is mostly preferred (86).
Steroids. Particularly in sepsis induced ALI, early, high-dose steroid administration may
decrease pathogen clearance, causes myopathy and reduces wound healing (130). It has been
stated that high dose of hydrocortisone for improvement in ARDS can be harmful as it did not
reduce mortality (93; 177). Literature suggested a benefit in starting corticosteroids within 72
hours of ARDS onset whereas others supported the use of corticosteroids in ALI prior to 14 days
from ALI onset (178). Low dose hydrocortisone had shown some beneficial effects but in a most
recent clinical trial even low dose corticosteroid administration did not reverse sepsis or septic
shock in patients with ALI (86).
Surfactants. Surfactant and edema proteins interactions lead to surfactant inactivation. As a result
there is reduction in surface tension in alveolar compartment that leads to atelectasis. Surfactant
administration has improved oxygenation in neonatal RDS, as well as infants, adult patients and
in animal model of ALI/ARDS but not mortality (135). H) Inhaled nitric oxide has shown to
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improve oxygenation in patients with ALI/ARDS, but could not improve mortality and has been
associated with acute kidney injury (179). It is used only as a rescue therapy for refractory
hypoxaemia (169).
Nutrition. Standard supportive care should be given to ALI/ARDS patients that include adequate
nutrition omega-3 fatty acid (eicosapentaenoic acid) along with gamma-linolenic acid caused a
marked attenuation in risk of mortality in some studies, risk of developing new organ failures,
time on mechanical ventilation, and ICU stay (180).
Anti-coagulants. Other therapies include prevention of DVT by using anticoagulants such as
LMW heparin or thrombolytics such as urokinase, streptokinase, tissue plaminogen activator
(181; 182).
Control of hyperglycemia. Hyperglycemia can be controlled by infusion of insulin, PPAR
agonist, ACE-1, metformin, HMG Co-A reductase inhibitors in septic patients with ALI (183).
B.4.3 Experimental Strategies

Human model of ALI, one lung ventilation (OLV), a technique required to facilitate lung
resection surgery, has been used to investigate potential biomarkers of VALI. Some studies have
shown that use of low tidal volume during OLV was associated with reduced biomarkers of
pulmonary and systemic inflammation whereas, high tidal volume and airway pressure resulted
in development of ALI (184; 185).
Several lines of evidence suggest that using beta agonists to treat acute lung injury (ALI)
or acute respiratory distress syndrome (ARDS) may be beneficial (186). Terbutaline, a short28

acting beta 2 adrenergic receptor agonist, increases the clearance of alveolar edema in lung
explants (187). Salbutamol, beta 2 adrenergic receptor agonist has also been administered in
animals for edema clearance (186). Intravenous salbutamol decreases alveolar-capillary
permeability in patients with ARDS, possibly by simulating alveolar wound repair (188).
Albuterol is not beneficial in improving ALI parameters during mechanical ventilation (189).
Inhaled salmeterol, a long-acting β2 adrenergic receptor agonist, reduces the incidence of highaltitude pulmonary edema (190). cAMP agonist and adenosine dependant signalling pathways
(A2BAR) are being studied for lung edema clearance during VALI (191).
Intravenous bone marrow mono nuclear cells administration has reduced inflammation,
alveolar collapse, interstitial edema (192). Intratracheal and intravenous administration of
mesenchymal stem cells have improved oxygenation and lung function as well as sepsis in mice
but in human engraftment of MSC in lung in patients with severe ARDS is still in trail phase
(193; 194).
Statins (simvastatin) have shown to reduce pulmonary dysfunction HARP-2 in ALI
patients (195).
B.4.4 Future approaches to ALI/ARDS management

Extra-corporeal carbon dioxide removal (ECCO2R) systems can be used to detect novel
biomarkers for VALI. In ALI/ARDS patients ECCO2R can be used to detect its effectiveness
along with low tidal volume strategies and inflammatory biomarkers or lung injury biomarkers,
(procollagen peptide III in lavage) can be detected.
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SECTION C
C. ENDOTHELIAL CELLS
C.1 Normal Physiology
The vascular endothelium is composed of 1-6 x1013 squamous epithelial cells that forms
the inner lining of blood vessels and lymphatic vessels and covers an area of 1-7m2 (196). The
healthy vascular endothelium regulates many aspects of vascular function, including vasomotor
tone, cellular and nutrient trafficking, blood fluidity, and participates in angiogenesis.
Endothelial cells release vasoactive molecules that include vasodilators nitric oxide (NO) and
prostacyclin and the vasoconstrictors (endothelin-1, ACE, thromboxane A2, and platelet
activating factor) that regulate arteriolar tone and maintain blood pressure.
Normal vascular endothelium is responsible for establishing an anti-thrombotic
environment. Endothelium maintains hemostasis by regulating the coagulation and fibrinolysis
cascade through production of von Willebrand’s Factor (VWF), which is stored in WeibelPalade bodies (0.1 µm wide by 3 µm long membrane-bound structures), thrombomodulin (TM),
and tissue factor plasminogen activator (t-PA). In part, the anti-thrombotic surface consists of
the endothelial glycocalyx, which is comprised of proteoglycans and glycoproteins incorporating
mediators secreted by EC, such as NO, prostacyclin, heparin and activated protein C, that
prevent platelet aggregation and clotting. (197-201).
The pulmonary endothelium participates in the exchange of water and solutes between the
blood and the interstitium through passive transport. Water transport occurs through endothelial
water transport channels called aquaporins. Under normal conditions, a small amount of fluid is
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filtered across the endothelial monolayer and drained through lymph. Tight and adherens
junctions between endothelial cells control this fluid filtration. Albumin and other
macromolecules are actively transported through cellular vesicles.
The endothelium is extremely important in the regulation of both innate and adaptive
immune responses, through interaction with pro- and anti-inflammatory soluble mediators as
well as with circulating inflammatory cells. The specialized morphology of endothelium controls
trafficking of leukocytes to the site of infection as well as permeability (202).
C.2 Endothelial structural heterogeneity

Although all vascular endothelial cells (ECs) share common functions, there is significant
heterogeneity between macrovascular and microvascular endothelial cells, as well as regional
variation in different vascular beds. Arteriolar endothelium plays an important role in controlling
vasomotor tone whereas post capillary venules are specialized for leukocyte adhesion and
transmigration.
Endothelial cells are classified as continuous or discontinuous. Continuous endothelial
cells are fenestrated or non-fenestrated. Nonfenestrated continuous endothelium is found in
arteries, veins, and capillaries of the lung, brain, skin and heart and is characterized by the
presence of tight junctions and adherens junctions. Molecules cross this through active
transcytosis by caveolae and vesiculo-vacuolar organelles or through clathrin coated pits for
endocytosis. Caveolae (70 nm in diameter) are present in all types of endothelium but are most
prevalent in capillaries that contain continuous nonfenestrated endothelium with the exception of
blood brain barrier where caveoli are rare (203-205).
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Fenestrated continuous endothelium is found in capillaries of exocrine and endocrine
glands, gastric and intestinal mucosa, choroid plexus, glomeruli, and a subpopulation of renal
tubules for increased filtration or increased transendothelial transport. Fenestrae are transcellular
pores (≈70 nm in diameter) that extend through the full thickness of the cell. The majority of
fenestrae that are transcellular pores (≈70 nm in diameter) possess a thin 5 - 6-nm
nonmembranous diaphragm. Fenestral diaphragms possess integral membrane glycoprotein PV-1
with the exception of the glomerular endothelium (206). Discontinuous fenestrated endothelium
is found in certain sinusoidal vascular beds, liver and bone marrow because they lack a wellformed basement membrane. It has large heterogeneous fenestrae (100 to 200 nm in diameter)
without diaphragms (205-207). It has few caveolae and contains clathrin-coated pits and vesicles
that play an important role in receptor-mediated endocytosis (208).
C.3 Endothelial functional heterogeneity

Endothelial cell function heterogeneity is also critical to understand pathophysiology of
various diseases. For example, pulmonary arterial endothelium expresses a large amount of
endothelial nitric oxide synthase (eNOS), and releases more nitric oxide (NO), than capillary
endothelium. Pulmonary microvascular and macrovascular endothelial cells exhibit certain
functional differences that include barrier properties, signal transduction, apoptosis, growth rate,
flow alignment and mechanosensing, proliferation, shape, organelle distribution , gene
expressions, cytoskeletal arrangements, ion channel expression and function.
Leukocytes transmigrate from blood to infected tissue through a series of cascade that
include capturing, adhesion, rolling, firm adhesion and transmigration. Initial capturing and
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adhesion of leukocytes involves ligands and endothelial selectins such as P-selectin and Eselectin. E-selectin is highly restricted to activated endothelial cells mainly in postcapillary
venules and in bronchial circulation (209; 210). Endotoxemia in mice has increased cell surface
P-selectin and E-selectin in all tissues including lung and mesentery, heart, brain, stomach,
pancreas, intestine, and muscle, but largest amounts of both selectins were found in lung, small
intestine, and heart (211). In another study, lipopolysaccharide administration to mice has
increased E-selectin mRNA expression 14.6-fold in the heart, 5.6-fold in the lung, 3.8-fold in the
liver, 18-fold in kidney, 5.3-fold in brain, and 0.6-fold in the spleen (212).
The important function of endothelium is to maintain hemostasis and maintains a balance
between coagulation and fibrinolysis. On procoagulant side, endothelial cells produce TF, PAI-1
and VWF (213). It has been documented that t-PA expression in mice endothelium was confined
to arteries of pulmonary system and central nervous system. However, after maturity t-PA levels
in brain becomes less in large arteries but persists in small vessels. PAI-1 expression is highest in
lung, followed by heart, brain, spleen, liver, and kidney in mice (207; 212). However,
endotoxemia has shown 187-fold increase in PAI-1 in the liver and 3-fold increase in spleen
(207).
Endothelial cells have remarkable heterogeneity in function, but still researchers are keen
to explore more functions that contribute to pathophysiology of many diseases.
C.4

Endothelial activation in sepsis
During sepsis, microvascular function is altered. Since microvascular EC regulate

microvascular function, septic microvascular dysfunction is largely due to endothelial cells being
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activated, injured or become apoptotic (196; 211; 214). Many studies have shown that EC can be
injured by many mediators in sepsis, such as iNOS, COX-1, COX-2, ACE, ECE, Matrix
metalloproteinase, viral or bacterial and other non-bacterial pathogens, cytokines, hypoxia,
glucose, ionizing radiation, temperature, mechanical trauma, drugs and poisons (196; 202; 211;
214-224).
There is no standard way to define endothelial activation in sepsis (225). However, many
researchers have described it as phenotypic change that occurs during sepsis from anti -adhesive
to proadhesive. As a result EC express adhesion molecules on the cell surface, such as P-selectin,
E-selectin, ICAM-1, and VCAM-1. These cell surface markers are involved in increased rolling,
strong adherence, and transmigration of leukocytes into tissue (197; 199; 226). Activated ECs
also recruit increased numbers of platelets to the blood vessel wall (227). Many studies have
reflected the importance of these adhesion molecules in sepsis (228).
Many have correlated endothelial activation with physiological phenomenon such as
coagulation, inflammation, sepsis, and related diseases. For example, changes in EC expression
of PAI-1 have been suggested as an important marker of EC activation. Others have
characterized endothelial activation as induction of cell surface proteins, adhesion molecules,
cytokines release, cytoskeletal disruption, cell shape, permeability (229-232).
There are many other molecules which have been studied and proposed to indicate EC
activation, such as VEGF, endothelin, ACE, and others. For example, under normal conditions,
VEGF signaling plays a critical role in homeostasis and is protective against EC barrier
dysfunction. VEGF binds to two receptors on endothelial cells, VEGF receptor (VEGFR) 1 and
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2. VEGFR1 is also known as Flt-1. In sepsis circulating levels of VEGF are increased which may
lead to increased vascular leak, leukocyte adhesion/trafficking, and thrombosis (233-236).
There is evidence that endothelial activation is clearly associated with poor prognosis in
various diseases including sepsis.
C.4.1

E-selectin

C.4.1.1 Role of E-selectin

E-selectin or ELAM (endothelial leukocyte adhesion molecule) is a 107-115 kDa
endothelial transmembrane glycoprotein (237; 238). It facilitates the binding of leukocytes and
certain lymphocytes to activated endothelium (239; 240). Phosphorylation of the cytoplasmic tail
of E-selectin may cause endothelial cytoskeletal changes that lead to permeability and facilitate
diapedesis of leukocytes (241; 242).
E-selectin shares the same PSGL-1 on leukocytes just like P-selectin (243). It has been
shown that soluble E-selectin is deficient in PSGL-1 knockout mice, suggested importance of
PSGL-1 in solubilization of E-selectin (244). Moreover, during inflammation E-selectin activates
β2 integrins, modulates leukocyte movement, involved in augmentation of reactive oxygen
species (245). Adhesion of leukocytes to endothelium also provide a link between E-selectin and
cytoskeletal proteins such as a-actinin, vinculin, filamin, and paxillin, focal adhesion kinase
(FAK), a tyrosine kinase localized to focal adhesions of adherent cells that facilitate leukocyte
transmigration through endothelium (246; 247).
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C.4.1.2 Expression of E-selectin

E-selectin is inducible. In non-placental tissues E-selectin expression appeared truly
endothelial specific. Recently, cardiac fibroblast has expressed E-selectin in response to
cytokines stimulation (248; 249). It is stimulated by LPS, IL-1, IL-13, TNF-α and IFN-γ (249;
250). Combinations of cytokines like TNF-α and IFN-γ increases synthesis of E-selectin (251).
E-selectin is transcriptionally regulated by NF-κB (252) and activator protein-1 (AP-1) (253)and
can be blocked by inhibitors of transcription, translation or cytokines, including actinomycin D,
cyclohexamide or transforming growth factor-β (TGF-β) (254-256). In addition, transcription
factors such as ATF-2/Jun plays an important role in the transient induction of the E-selectin
mRNA in EC (257). Moreover, endothelium-specific histone modifications and chromatin
remodeling at the E-selectin promoter also contributes to the induction of E-selectin gene due to
involvement of coactivators p300 and IκB kinase (258; 259). Some other unidentified regulatory
factors such as HOXA9, also contribute to induction of the E-selectin gene post TNF alpha
stimulation (260).
In HUVEC, strong expression of E-selectin has been detected at 4 and 24 hrs after IL-1β
stimulation and returned to baseline after 24 hrs (239; 261; 262). Four important regulatory
elements have been identified in E-selectin promotor that contributes to E-selectin expression
upregulation during sepsis. Three of these are NF-KB binding sites whereas, one is ATF binding
element. NF-KB binding elements are not sufficient for E-selectin expression induction post
cytokines stimulation. Therefore, ATF binding sites plays a significant role in E-selectin
expression upregulation after cytokine stimulation. TNF alpha has been shown to upregulate E37

selectin expression through activation of three important signaling pathways NF-KB, JNK1, P38
(263).

C.4.1.3 E-selectin in diseases

Polymorphism of the E-selectin gene in humans is associated with early onset, severity of
sepsis (264). E-selectin gene polymorphism is caused when serine is replaced by arginine at
position 128(265). Studies have shown that polymorphism has altered E-selectin ligand binding
by enabling E-selectin to recognize heparin or the non-fucosylated sialyl lactosamine precursor
of sLeX abnormally (266). The defect in the GDP-fucose transporter and lack of α1,3
fucosylated carbohydrate ligands that binds to selectins resulted in leukocyte adhesion deficiency
II (LAD II) in humans. Patients with LAD II suffer not only from a less severe form of infection
but also from severe psychomotor and growth retardation. The endothelium in LADII also
retains reduced expression of fucosylated leukocyte L-selectin ligands. Human LADII patients
resemble mice that lack L, P and E selectin genes and therefore there is leukocytosis, reduced
rolling migration of neutrophils to the site of infection (267).
Appropriate fucosylated selectin ligands, namely Lewis carbohydrate antigens, are
critical in leukocyte recognition of selectins and in leukocyte migration to the site of
inflammation. Phosphorylation of the cytoplasmic tail of E-selectin may cause endothelial
cytoskeletal changes that lead to permeability and facilitate diapedesis of leukocytes (241; 268).
Ligation of E-selectin by L-selectin, PSGL-1 and/or CD44 expressed on leukocytes causes
activation of αMβ2 (CD11b/CD18, Mac-1) on the leukocyte surface through phosphorylation of
38

p38 and p42/44 MAPKs, which causes neutrophil recruitment through the endothelium to
inflamed tissue (269). However, p38 MAPK specific inhibitor BIRB 796 BS has significantly
reduced plasma E-selectin expression after LPS administration in human (270).
During inflammation E-selectin has activated β2 integrins, modulated leukocyte
movement and involved in augmentation of reactive oxygen species (269; 271). Adhesion of
leukocytes to endothelium also provide a link between E-selectin and cytoskeletal proteins such
as a-actinin, vinculin, filamin, and paxillin, focal adhesion kinase (FAK), 2’1 a tyrosine kinase
localized to focal adhesions of adherent cells that facilitate leukocyte transmigration through
endothelium.
C.4.1.4 E-selectin in sepsis

Various studies have used endothelial E-selectin as a marker of sepsis, severe sepsis,
septic shock and other sepsis related diseases. In human patients, E-selectin gene expression,
soluble E-selectin expression and endothelial cell surface E-selectin are elevated in sepsis and
sepsis related disorders like ALI (239; 261-263). In another study, during early sepsis, exposure
to hypoxia and arterial hypertension was associated with increased E-selectin expression in
human patients (272).
In experimental animals and in cell culture, a variety of endothelial cells have expressed
E-selectin in response to septic stimulation (239; 261-263). In mice, E-selectin mRNA levels in
both pulmonary and hepatic microvascular endothelial cells are dramatically increased at 3 hours
post CLP, then they returned to basal level at 12 hours post CLP (272; 273). In another study,
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soluble E-selectin levels are elevated post CLP and in mice 12 and 24 hrs (272; 274). LPS has
been shown to activate TLR2 that has affected endothelial activation, coagulation in sepsis (272;
272; 275; 276). TLR2 agonists, such as peptidoglycan-associated lipoprotein, Pam3Cys, and
murein lipoprotein have been shown to induce E-selectin expression in HUVEC, human lung
microvascular endothelial cells (HLMVEC) (272; 272; 277; 278).
Similarly, mice when intravenously administered with TLR2 agonists, mRNA levels of
E-selectin in lung and soluble E-selectin level in plasma were augmented. In mice, cytokines like
TNFα have shown to increase E-selectin expression in lung microvascular endothelial cells.
Interestingly, TNF receptor 1 (TNFR1) or p 55 signaling contributes to E-selectin expression
upregulation in lungs in sepsis (279). TNFR1 is shed by proteolytic cleavage by the
metalloproteinase TNF α converting enzyme (TACE or ADAM17) in sepsis from HUVEC and
mice LMVECs. Recently, it has been documented that by blocking TNFR1 shedding,
inflammation is increased in mice. Similarly, preventing TNFR1 shedding from endothelial cells
by inhibiting mitochondrial Ca++ or ROS (H2O2) has also augmented E-selectin expression in
lung microvessels under septic conditions. This suggests mitochondrial ROS protects endothelial
activation or decrease E-selectin expression in sepsis (280).
In a co-culture model, septic stimulation has increased or decreased E-selectin expression
in endothelial cells in the presence of other cells. In a co-culture cell model, neutrophils have
enhanced E-selectin expression in endothelial cells (HUVEC) after septic stimulation like TNF
alpha (281). In a co culture model, HUVEC in the presence of whole blood cells or mononuclear
cells pretreated with biomaterial (polysterene) augmented E-selectin expression in HUVEC after
4 hours of static co- culture. Similarly, the presence of ‘more secretory VEGF’ human aortic
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smooth muscle cells with human aortic endothelial cells has increased E-selectin in HAEC after
stimulation with biomaterial treated mononuclear cells or fMLP (282). In another cell culture
model, E-selectin in medium and on HUVEC cell surface is increased when HUVEC were
treated with THP-1 culture medium containing LPS/human plasma (283). There is little direct
evidence for neutrophil effects on pulmonary microvascular EC E-selectin expression.
Many other cells have shown to suppress E-selectin expression in endothelial cells in
sepsis. Such as, in a bilayer with EC, alveolar epithelial cells A549 reduced expression of Eselectin on the EC in response to LPS, but not after TNF-alpha stimulation (284).
Surface expression of E-selectin leads to either shedding, or slow internalization from the
endothelial surface to lysosomes for degradation. Due to smaller size and MW, circulating Eselectin is considered as a microparticle that possesses the ability of leukocytes binding. It has
been reported that lower cell surface levels of E-selectin found in sepsis are not necessarily
related to shedding of E-selectin. E-selectin is clustered in lipid rafts and clathrin coated pits but
is internalized by clathrin coated pits. Localization of E-selectin at both regions facilitate
neutrophil rolling under flow free conditions (285).
Circulating levels of soluble E-selectin (sE-selectin) are increased in a variety of
diseases, such as sepsis and other inflammatory disorders, hypertension, diabetes, and
hyperlipidemia (233; 240; 269; 283; 286). Soluble E-selectin has been detected in supernatants
of cytokine-activated endothelial cells and is elevated in serum levels of septic animals, and in
patients with sepsis, ALI, hypertension, diabetes, and hyperlipidemia. For example, single
intravenous injection of lipopolysaccharide (LPS; 4 ng/kg) has shown to increase sE-selectin in
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early septic human patients (287). As well, human patients with severe acute pancreatitis (SAP)
had elevated levels of sE-selectin and endothelial permeability in patients with sepsis as
compared to people without sepsis or healthy volunteers (288; 289). Low dose prednisolone has
shown beneficial effects in the treatment of the ARDS and septic shock. Levels of sE-selectin
were prevented by a low dose of (3mg) prednisolone but maximal inhibition occurred with the
highest dose of prednisolone 30 mg in a human endotoxemia (289).
In short, the evidence strongly suggests that E-selectin expression is a marker of EC
activation under inflammatory conditions, such as sepsis.
C.4.2 PAI-1
C.4.2.1 Role of PAI-1

PAI-1 is a 50-kDa glycoprotein that is a member of the serine protease inhibitor (serpin)
family. PAI-1 is involved in vivo in inhibition of both tissue- and urokinase-type plasminogen
activators (290). In addition, PAI-1 acts as an acute-phase protein in periods of acute
inflammation. PAI-1 has 3 isoforms in the blood circulation: active, inactive, and a latent form.
The active form converts transiently into the latent form with a half-life of 1 h. The latent form is
more stable and can also be reconverted into the active form when complexed with vitronectin.
PAI-1, urokinase and tissue type plasminogen activator inhibitor, is constitutively expressed by
endothelial cells and then stored in sub cellular matrix bound to vitronectin (291; 292). The halflife of PAI-1 can be increased when endothelial or platelet derived PAI-1 is complexed with
vitronectin. Vitronectin/PAI-1 complex is an inhibitor of activated protein C (APC) and
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thrombin in the absence of heparin. The detachment of PAI-1 from extracellular matrix induces
F-actin in endothelial cells that causes cytoskeletal rearrangement and cell morphology changes
(293)
C.4.2.2 Expression of PAI-1

PAI-1 is synthesized by a number of cells in vitro e.g., hepatocytes, endothelial cells,
platelets, smooth muscle cells, adipocytes, cardiac myocytes and tumor cells. It has been
reported that PAI-1 is found in the alpha-granules of platelets, where PAI-1 is primarily stored in
the latent, free form (∼90%) and is released after vessel trauma. The normal human plasma level
of active PAI-1 is 5-10 ng/ml.

PAI-1 can be measured either as PAI-1 activity or as PAI-1

antigen. PAI-1 antigen exists as an active, inactive, latent or free form, or in complex with
vitronectin, tissue plasminogen activator, or both (291; 294). The secretion of PAI-1 is regulated
by a number of agents, such as TNF-α, IL-1β, transforming growth factor–β, endotoxin, verylow-density lipoprotein, glucose, glucocorticoids, and insulin, angiotensin II and estrogen. PAI-1
is removed from the circulation by the liver and also is regulated by endothelial inactivation.
PAI-1 plasma level undergoes a circadian pattern, which shows peak levels in the early morning.
C.4.2.3 PAI-1 in diseases

It has been documented that endothelial cell PAI-1 mRNA level, cell surface expression
and soluble levels in circulation are increased during sepsis, sepsis induced lung injury and other
cardiovascular diseases. Moreover, increased PAI-1 levels play important role in the
pathogenesis of acute lung injury, pulmonary edema, and DIC. PAI-1 may also contribute to
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vascular permeability during early lung inflammation. However, at later hours PAI-1 contributes
to resolution of lung inflammation as disruption of PAI-1 at later stages increased mortality in P.
aeruginosa induced pneumonia in mice (295).
C.5 Role of Endothelial cells in sepsis
C.5.1 Increased permeability

Sepsis induces endothelial damage that leads to increased capillary permeability. Sepsis
upregulates endothelial adhesion molecules that interact with neutrophils and result in rolling,
adhesion and migration of neutrophils through endothelium that results in increased endothelial
damage and increased permeability. Moreover, angiopoietins such as angiopoietin-2 is involved
in sepsis induced increased permeability and associated with increased mortality in septic
patients (296). In contrast, endothelial damage is prevented when angiopoietin-1 binds with Tie2 receptor (297). In addition, VEGF and its receptor (fms like tyrosine kinase-1) are also
associated with increased permeability during sepsis or septic ALI (298).
C.5.2 Proadhesive properties

Activated endothelial cells exhibit proadhesive property during sepsis or septic ALI. As a
result leukocytes or platelet adhere to damaged endothelium. Adhesion of leukocytes on
endothelial cells triggers ROS production, increases upregulation of P-selectin, E-selectin,
ICAM-1, VCAM-1 on cell surface. Adhesions of platelets to endothelial cells result in platelet
aggregation and thrombosis (233; 240; 269; 283; 286; 280)
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C.5.3 Procoagulant properties

There are many factors that activate endothelial cells such as complement, cytokines,
chemokines, serine proteases, fibrin, activated platelets and leukocytes, hyperglycemia, and/or
changes in oxygenation or blood flow. Inflammatory mediators activate endothelial cells to
induce a net procoagulant phenotype. Many studies have shown that LPS and cytokines can
inhibit expression of the anticoagulant factor TM, decrease APC, t-PA, heparin and increase
expression of TF and PAI-1 to generate procoagulant microparticles (291; 292; 293). Sepsis
associated changes in TM expression varies between organs. In mice, the administration of LPS
has resulted in reduction in total tissue TM antigen in the lung and brain, but not in the kidney
(299). In sepsis, endothelial cells activate neutrophils, platelets, monocytes that are also capable
of initiating coagulation. Moreover, endothelial cells undergoing apoptosis also amplify
coagulation process.
In various models of sepsis, and in humans fibrin deposition has been observed in various
organs. In a mouse model of endotoxemia, LPS administration has resulted in fibrin deposition in
the kidney, adrenal gland, lung (300). Still others have shown that LPS injection in wild-type
mice has increased fibrin levels in the kidney, liver, and myocardium, but not the lung (301). In a
baboon model of sepsis, the lethal doses of E.coli administration has resulted in increased fibrin
deposition in the marginal zone and sinusoids of the spleen, the hepatic sinusoids, the glomeruli,
and peritubular vessels of the kidney, but little or no fibrin in the portal vessels of the liver,
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cerebral cortex, skin, myocardium, or aorta (302). These studies reflect the association between
sepsis and coagulation.

C.6 Role of Endothelial cells in ALI-ARDS
C.6.1 Endothelial activation

During septic ALI, endothelial cells are activated and upregulate adhesion molecules (Pselectin, E-selectin, ICAM-1, VCAM) that are important for leukocyte recruitement, adhesion
and transmigration into interstium and alveolar region (210; 211; 302). In various diseased
animal models and clinical models, these adhesion molecules are increased and found in lung
and serum. These molecules are upregulated after endotoxemia/ LPS and cytokines (TNF alpha,
IL-1 beta) through various signaling pathways (220; 263). Transudation of plasma proteins into
airways promotes formation of a fibrin matrix deposition that can lead to pulmonary fibrosis due
to increased levels of PAI-1. Whereas, Plasminogen activators (PA), urokinase PA (uPA) and
tissue-type PA (tPA), convert plasminogen to plasmin, which in turn lyses fibrin matrices and
thereby exerts anti-fibrotic and protective effects in ALI patients (201; 287).
C.6.2 Endothelial Injury / Barrier Dysfunction

Sepsis induces endothelial damage that causes endothelial barrier dysfunction. Lung
inflammation is associated with increased pulmonary microvascular (PMV) permeability leading
to exudation of plasma proteins into alveolar spaces, interstitial edema, impaired gas exchange,
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increased morbidity and mortality. Numerous efforts have been made to understand how
endothelial barrier function is lost during early sepsis, but this knowledge will be beneficial to
prevent excess permeability from developing and to improve clinical outcome (223; 303).
Cultured pulmonary microvascular endothelial cells (PMVEC) represent an attractive model for
the study of barrier function.
Increased alveolar capillary barrier dysfunction is a result of endothelial actin cytoskeletal
damage, epithelial cell damage, loss of integrity between cell connections (tight and adheren
junctions) which leads to pore formation (223; 303).
Evidences suggested that there is an interaction between iNOS, cytoskeleton and junctional
proteins and protein leak. iNOS is induced by LPS and cytokines TNF alpha and IFN gamma.
iNOS plays an important role in disrupting junctional proteins. It has been documented that
disrupted F actin formation has potentiated LPS induced iNOS expression. Moreover, iNOS
induction followed by cytokines has relocated VE cadherin to the site of leak (304). It has been
stated that LPS mediates protein leak / endothelial barrier dysfunction through various pathways.
In animal model of ALI, LIMK1 which is activated by RhoA/Rho kinase pathway, is involved
RhoA-dependent disruption of endothelial barrier function. Inhibition of LIMK1 by using
LIMK-/- animals has reduced protein leak and neutrophil influx in lungs (216). In other animal
models of sepsis induced ALI, fusadil (specific ROCK inhibitor) reduces protein leak and
leukocyte adhesion by reducing iNOS in endothelial cells and increasing eNOS. This suggests
that iNOS expression is also altered when Rho is down-regulated due to changes in actin
cytoskeleton structure. Clinical evidences suggested that there is elevated soluble cadherin levels
found in ARDS patients serum and in animals.
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C.6.3 Endothelial apoptosis

Apoptosis is a process that is important for development and homeostasis. Resting
endothelial cells exhibit very low apoptotic cells whereas during sepsis and related ALI/ARDS,
pathogens are capable of inducing endothelial cell apoptosis. Much evidence suggests that LPS,
TNFα, IL-1β, IFNγ, oxygen free radicals, hypoxia can induce apoptosis in endothelial cells. LPS
can up-regulate Bcl-2 homologue, A1, and the zinc finger protein, A20, in cultured endothelial
cells. It has been stated that LPS or cytokines administration in mice has caused pulmonary
endothelial cell apoptosis. Apoptotic endothelial cells contribute to IL-1–dependent paracrine
induction of ICAM-1 and VCAM-1, increased production of reactive oxygen species (ROS),
increased procoagulant activity, decreased production of prostacyclin, and activation of
complement. Endothelial cells undergoing apoptosis has shown increased binding to
nonactivated platelets – This suggests this binding of apoptotic endothelial cells may contribute
to thrombotic events.
C.7 Treatment of Endothelial Dysfunction

Various non-pharmacological and pharmacological approaches have been shown to
improve endothelial dysfunction.
C.7.1 Non-Pharmacological Approaches
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Stem cells such as mesenchymal, bone marrow, placental, amniotic fluid, neuronal,
adipose tissue derived, hair follicle stem cells have improved endothelial dysfunction.
C.7.2 Pharmacological Approaches

Oxidative stress, the main pathophysiologic mechanism that impairs NO bioavailability
and endothelial dysfunction, has become subject of interest of many researchers. The use of
high-dose antioxidant vitamins (Vitamin C and E) became effective in restoring normal
endothelial function in many studies (305). Other antioxidant compounds, such as the flavonoids
contained in red wine and chocolate, have been found to improve endothelial function in
amimals (306).
Other mechanisms include the upregulation of eNOS expression, the enhanced NO
release, their antioxidant activity, and the reduced expression and synthesis of endothelin-1 can
improve endothelial function.
Antihypertensive β-blockers and diuretics have little or no effect on endotheliumdependent vasodilation. In contrast, newer β-blockers such as Nebivolol cause vasodilation by a
direct effect on NO synthase and by its antioxidant effect and carvedilol was able to reduce ROS
generation and improve endothelial dysfunction.
ACE inhibitors and angiotensin receptor blockers have shown antioxidant and antiinflammatory effects. Accordingly, ACE inhibitors and angiotensin receptor blockers have been
shown to improve endothelium-dependent vasodilation in many experimental studies. Calciumchannel blockers have been consistently shown to reverse impaired endothelium-dependent
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vasodilation, mainly in the microcirculation. Statins has improved endothelial dysfunction by
reducing LDL cholesterol levels and increasing HDL cholesterol.
Glitazones (insulin-sensitizing agents used to treat patients with type 2 diabetes) have
been beneficial for endothelial cell function. Both Rosiglitazone and Pioglitazone have improved
endothelial function in obese and diabetic patients. In septic patients, Glitazones has reduced
levels of asymmetric dimethylarginine, a competitive inhibitor of eNOS, and decreased ROS
production and inhibited vascular inflammation.
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SECTION D
D.

NITRIC OXIDE

Nitric oxide (NO) is a free radical, produced by conversion of L-arginine to L-citrulline
in the presence of nitric oxide synthase (NOS). NOS enzyme is made up of 2 identical monomers
which have 2 domains, Carboxy-terminal reductase domain and amino or N-terminal oxygenase
domain. C-terminal reductase binds to flavin adenine dinucleotide FAD, NADPH, FMN flavin
adenine mononucleotide. Whereas, the N-terminal oxygenase binds to co-factors like haem, BH4
and L-arginine. Electrons are transferred from NADPH of reductase domain to haem in
oxygenase domain of opposite NOS dimer in the presence of calmodulin binding site and as a
result there is conversion of L-arginine to L-citrulline and NO. The N-terminal oxygenase
domain catalyses the conversion of arginine into citrulline and NO (307; 308).
Synthesis of NO occurs in two steps. First, NOS hydroxylates L-arginine to Nv-hydroxyL-arginine which remains attached to the enzyme and in the second step, NOS activates O2 and
oxidizes Nv-hydroxy-L-arginine to L-citrulline and NO. However, L-citrulline has been
introduced as another NO donor through NOS dependent pathway via conversion of L-citrulline
to L-arginine (308). Whereas, NO2, NO3 also contributes to NO synthesis via NOS independent
pathway.
D.1

NO Physiology

NO is highly reactive lipophilic free radical produced by variety of mammalian cells.
Normal levels of nitric oxide (NO) in the body are important to regulate homeostasis in the cells,
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tissues and organs, neurotransmitter of central nervous system, regulation of cell growth,
mitochondrial respiration, prevent platelet aggregation and leukocyte binding to endothelial cells.
NO is released for short periods of time (few seconds) following the enzymatic activation
of constitutively expressed endothelial NO synthase (eNOS; type 3) or neuronal NO synthase
(nNOS; type 1). In contrast, inducible NO synthase (iNOS; type 2) has been suggested to be
responsible for the profound and long-lasting production of NO. Nitric oxide diffuses within
endothelial cells, to the luminal surface of the endothelium, and into the smooth muscle cells of
the vascular wall, where it initiates signaling via guanylate cyclase to produce cGMP and by
direct S-nitrosylation of cysteine residues in proteins, to activate transcription factors NF-κB and
AP-1 and to inhibit Ca2+-dependent vasoconstriction (309).

D.2 Nitric Oxide Synthesis
D.2.1 eNOS

The main source of endothelial NO is eNOS which is associated with caveole but it is
also present in cardiac myocytes, platelets, and certain neurons, in syncytio-trophoblasts of the
human placenta and in LLC-PK1 kidney tubular epithelial cells. It is also present in golgi
apparatus membranes. It is constutively and abundantly expressed in the lungs.
Increased intracellular calcium lead to increased levels of calmodulin and the increased
binding of calmodulin to eNOS and nNOS that causes increased NO production. eNOS activity
depends on Ca++ for generation of NO from eNOS. Its expression increases by hypoxia, shear
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stress, VEGF, insulin, bradykinin, estrogen (310-313). After fluid shear stress stimulation, eNOS
can also be activated and do not produce sustained release of intracellular Ca++, but still release
long lasting NO through phosphorylation of eNOS protein on serine (Ser), threonine (Thr), and
tyrosine (Tyr) residues. Ser1177 and Thr495 are important phosphorylation sites in human
endothelial NOS. However, Ser1177 is not phosphorylated in resting human endothelial cells.
Endothelial cell-derived NO plays an important role in vascular physiology, regulating
blood flow and vessel wall remodeling through direct effects on vascular smooth muscle cells.
Many studies reported that by deleting eNOS gene in animals, blood pressure is increased (313;
314). Nitric oxide by eNOS that is released towards the vascular lumen inhibits platelet
aggregation and adhesion to endothelium (315). It also inhibits the release of platelet-derived
growth factors that stimulate smooth muscle proliferation and its production of matrix molecules.
eNOS derived NO inhibits leucocyte adhesion to endothelium (316) by either interfering
with the ability of the leucocyte adhesion molecule CD11/CD18 to bind to the endothelial cell
surface or by suppressing CD11/CD18 expression on leucocytes.
eNOS-derived NO plays a critical role in post-natal angiogenesis. The lung phenotype of
eNOS-deficient mice mimics alveolar capillary dysplasia in humans that leads to vascular
dysfunction and respiratory disorders. Endothelium derived NO prevents endothelial cell
apoptosis and contributes to anti-inflammatory process.
D.2.2 nNOS
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Neuronal NOS (nNOS) is found in neural tissue in brain, in spinal cord, in the
sympathetic ganglia and adrenal glands, in peripheral nitrergic nerves (nerves that contain nNOS
and generate NO), in epithelial cells, in kidney macula densa cells, in pancreatic islet cells, and
in the vascular smooth muscle and in skeletal muscle and in myocardium.
nNOS contains a PDZ domain to interact with the PDZ domains of other proteins to
determine enzyme activity. Similar to eNOS, Ca2+-dependent calmodulin activation is important
for the regulation of nNOS activity to generate NO. nNOS is also constitutively expressed.
However, its expression is changed by hypoxia. nNOS-derived NO acts as a neurotransmitter,
plays an important role in synaptic signaling events like nNOS mediates long-term regulation of
synaptic transmission, learning, memory, regulation of blood pressure. Inhibition of nNOS leads
to hypertension (317; 318). Therefore, nNOS plays an important role in maintaining vascular and
microvascular tone.
D.2.3 Mitochondrial NOS (mt NOS)

Mitochondrial NOS (mtNOS) was first recognized as the neuronal isoform (nNOSα) with
postranslational modifications in heart and liver. It is also found in skeletal muscle, diaphragm
and kidneys and in endothelial cells and breast cancer cells. The localization of NOS in
mitochondria is still in debate. Whether it is bound to mitochondria or any other organelles or
cytoplasm is still a question. Previous evidences suggested that it can be inhibited by antibodies
to iNOS but not to nNOS or eNOS. Further studies regarding its localization will help to
understand mechanisms. Mitochondrial NOS contributes to septic shock myocardial depression
(319).
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D.2.4 iNOS

iNOS has been recognized by almost every cell type and is localized to membranes and
cytosol of cells (320). Unlike eNOS and nNOS, iNOS activity is independent of calcium levels
because of very tight calcium-calmodulin binding. Thus, iNOS can bind to calmodulin at very
low concentrations of calcium but its activity is not increased in response to any fluctuations in
calcium level. Consequently, iNOS tends to generate long lasting and much higher
concentrations of NO than nNOS and eNOS. It has been reported that iNOS yields NO
approximately 100 to 1000-folds for several hours after septic stimulation.
The functional iNOS enzyme is a homodimer. Homodimerization of iNOS depends on
the availability of cofactors such as tetrahydrobiopterin (BH4), haem and L-arginine (321). iNOS
has much more tendency to uncouple and generates superoxide in case of limited L-arginine or
BH4. L-arginine availability can be reduced due to production of NO. Competition between Larginine and arginase (competitive substrate) occur due to Vmax of arginase is greater than 1000
fold that reduces the bioavailability of L-arginine for NOS, therefore limiting NO production.
Consequently, there is increased formation of L-proline and polyamine which contributes in
collagen synthesis and cell proliferation that contributes to pathophysiology of lung injury,
hypertension and asthma. Super oxide when reacts with surrounding NO, it produces
peroxynitrite. Therefore, reduced bioavailability of L-arginine also affects cell proliferation and
Tetrahydrobiopterin (BH4) another co-factor, which is also a form of reduced biopterin and can
be oxidized to biopterin when reacts with peroxynitrite. Peroxynitrite oxidation of BH4 can be
responsible for raised superoxide production instead of NO yield (322).
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iNOS activity is also affected by other proteins such as kalirin blocks iNOS activity by
inhibiting enzyme dimerization. Another protein named NAP110 (a 110-kDa protein) has been
found in mice macrophages can directly interacts with the amino terminus of iNOS and inhibits
dimerization and thus affects NOS activity. In addition, iNOS has been reported to interact with
calcium/calmodulin-dependent protein kinase II (CaMKII) in rat vascular smooth muscle cells.
iNOS or iNOS activity is responsible for several physiological functions in cells. For
instance, high concentrations of NO produced by endothelial cells interferes with DNA and
causes DNA fragmentation (323). Furthermore, endothelial cells can lyse tumor cells post
cytokine stimulation. Similarly, nitrogen oxide formed by hepatocytes post cytokine stimulation
has been useful in killing malarial sporozoites. In addition, iNOS derived NO inhibits enzymes
that contain iron such as complexes I and II (mitochondrial electron transport chain),
ribonucleotide reductase (involved in DNA replication) and cis-acotinase (involved in kreb
cycle). In brief, iNOS activity contributes enough to modulate cellular physiology or associated
mechanisms.

D.3 Role of NO in disease

NO is highly reactive gaseous free radical produced by all mammalian cells. NO
overproduction has been implicated in pathogenesis of various infections and cardiovascular
diseases such as hypertension, atherosclerosis, coronary heart disease and cardiomyopathy,
sepsis, ALI/ARDS, asthma, diabetes, renal failure. Moreover, NO, NO metabolites nitrates,
nitrites and other RNS such as peroxynitrite (ONOO-) and nitrogen dioxide (NO2) are thought to
56

be involved in these diseases. High levels of NO metabolites has been found in plasma and BAL
of septic patients and in animal model of sepsis and sepsis induced lung injury (309; 317; 318;
321; 323-328). However, the mechanism of NO involved in pathogenesis of sepsis or sepsis
induced lung injury is still controversial.
BH4 performs various functions in regulating NOS activity such as it converts the NOS
haem iron to a high-spin state, promotes arginine binding; BH4 bound to NOS acts as a redoxsensitive co-factor; BH4 increases substrate affinity of NOS; BH4 facilitates in electron transfer
as it converts to BH3, and it stabilizes NOS dimer formation, which is important for functional
NOS activity. When BH4 is limited, NOS dimer is altered that result in uncoupling of NOS
dimer which is associated with many diseases (322). As it has been documented that BH4
deficiency converts neuronal NOS into peroxynitrite synthase, which increases neuronal
vulnerability/susceptibility to hypoxia-induced mitochondrial damage and necrosis and affects
phenylalanine hemostasis and other disorders like phenylketonuria (PKU). Addition of BH4 to
eNOS and nNOS results in production of NO whereas, deletion of BH4 results in uncoupling of
oxygen reduction. Increased oxidized forms of BH4, especially dihydrobiopterin (BH2), has also
been reported in oxidative stress related diseases like arteriosclerosis. Therefore, anti-oxidant
like ascorbic acid/vitamin C has played an important role in maintaining BH4 in vascular
disorders. BH4 has also played a beneficial role in diseases. BH4 administration has increased
iNOS gene level and improved survival in Ischemic /reperfusion animals by increasing NO
derived from iNOS. During hypertension, BH4 administration improves endothelial dysfunction.
It has been reported that L-arginine can influence NO production. Under conditions of
reduced substrate (like L-arginine) or cofactor availability like BH4, all NOS can also produce
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superoxide and peroxynitrite mediated tissue injury. Reduced and increased concentrations of Larginine contribute to uncoupling of iNOS. Moreover, lack of L-arginine or its availability has
shown detrimental effects on cells and tissues post septic stimulation which results in ONOOproduction. Various mechanisms of L-arginine deficiency has been documented in sepsis and
cardiovascular diseases. Increased activity of arginase-1 and iNOS has contributed to decreased
plasma arginine and L-arginine availability for eNOS during sepsis and endotoxemia. However,
L-arginine supplementation could not increase intracellular NO production despite increased
plasma arginine availability. Contrary to this, L-citrulline supplementation during sepsis and
endotoxemia has improved intestinal microvascular perfusion, plasma and tissue concentration
of L-arginine, citrulline and intracellular NO production, eNOS phosphorylation and decreased
iNOS protein level.
Abnormal nNOS derived NO signaling has been involved in pathophysiology of many
diseases like Stroke, Alzheimer, Parkinson, multiple sclerosis. Not only in these diseases, nNOS
derived NO has played a detrimental role in sepsis, septic shock and ALI (329). Evidences
suggested that NO produced from nNOS has impaired vasodilation in rat skeletal muscles under
septic conditions. Nonselective NOS inhibition in sepsis models has improved sepsis-induced
hemodynamic disorders. Recently it is stated that selective inhibition of nNOS has reduced ALI
by reducing oxidative and nitrosative stress markers (330).
It has been documented that mtNOS derived NO has been involved in pathophysiology of
many diseases including sepsis and septic shock (319). It has been found that NO produced by
mt NOS is upregulated by LPS and other septic conditions like CLP. However, its expression is
downregulated by ANG II, insulin and thyroid hormones and environmental conditions as cold.
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Nitric oxide has been involved in several cellular functions including reversible regulation of
mitochondrial respiration. NO reacts with superoxide to form peroxynitrite that has been
involved in modulating cellular functions and mitochondrial dysfunction and organ failure. Mt
derived NO also causes nitration and oxidization of mitochondrial and cell proteins and lipids
that plays a critical role in neurogenerative and metabolic disorders.
iNOS expression can be constitutive in some cells/tissues, but in many cells, its expression
is commonly and highly induced by a variety of inflammatory mediators like LPS, TNF alpha,
IL-1 beta, INF gamma in almost all type of cells. However, recently it has been reported that
human blood monocytes could not induce iNOS gene expression after LPS/cytomix treatment
(309; 311; 320; 329; 330). In many cells types its gene expression is detectable at 2-4 hrs and
peaked at 8 hrs and then declines after stimulation. iNOS is also regulated by phosphorylation.
Previous literature reported that protein kinase B (Akt), transcription factors such as nuclear
factor (NFkB) (311; 331) and activator protein-1 (AP-1), mitogen-activated protein kinase
(MAPK) p42/44 or extracellular signal-regulated kinase (ERK1/2) plays a significant role in
regulation of iNOS activity or expression in cardiovascular tissues.

D.3.1 Role of NO in sepsis

NO is highly reactive free radical and is produced by variety of cells during sepsis and
ALI. Its co factor L-arginine availability has been contributed to the production of NO. It has
been documented that impaired arginine production from citrulline also reduces NO production
in septic human patients and in mice patients. L-arginine administration during endotoxemia has
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also proved to be beneficial in improving intestinal microvascular perfusion and increased NO
production, increased eNOS phosphorylation and decreased iNOS protein (332).
NO donors or exogenous NO supplementation showed variability with respect to the NO
synthesis cascade and caused low blood pressure, which limits their use in septic shock models.
Recently, early phase of endotoxemia is protected against LPS-induced lung injury by NO
administration along with S-nitroso-N-acetylpenicillamine. Tolerance property, especially to
organic nitrates, also restricts their therapeutic application. Another new approach of using stable
S-nitroso-human--serum-albumin (S-NO-HSA) in the treatment of septic shock in an
endotoxemic rat model has been launched.
NO also decreases platelet and leukocytes adhesion to the endothelium. Role of NO is still
under debate depending on source of NO production under different septic conditions. NO
derived from constitutive endothelial nitric oxide synthase eNOS and nNOS have downregulated
P-selectin, E-selectin, ICAM-1 VCAM-1 and as a result there is decreased platelet and leukocyte
adhesion during sepsis (333). During early phase of endotoxin administration, NO produced by
eNOS plays a cytoprotective role of NO in lungs. eNOS does not contribute to basal E-selectin
upregulation and after septic stimulation in endothelial cells. Recently, eNOS is found to be
activated by TNF-α through S1P receptors, activated by sphingosine-1-phosphate (Sph1P)
produced through neutral-sphingomyelinase-2 (N-SMase2) and sphingosine-kinase-1 (SK1)
activation contributes to inhibition of E-selectin in HMVEC and HUVEC. This variability can
depend on cell type being studied.
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In contrast, iNOS derived NO has shown detrimental effects in sepsis or septic shock
animal models and human. Evidence suggests that during LPS administration in septic or septic
shock models, iNOS derived NO caused abrupt release of lipid mediators (platelet-activating factor, thromboxanes, leukotrienes) and cytokines (tumor necrosis factor-α, interleukin (IL-2, IL-6,
IL-8) (333; 334). In addition, during later phase of LPS administration, iNOS derived NO has
decreased blood pressure along with vasoplegia, tissue hypoperfusion, microvascular damage,
and multiple organ injury. NO produced from iNOS has increased prostaglandins production in
in vivo and in vitro models of sepsis. It is also involved in reduction of eNOS during sepsis.
During sepsis, heat shock protein 90 has been involved in regulation of NO. In various septic
models, hsp 90 inhibitors has improved survival, lung injury and decreased formation of hsp90iNOS complexes and NO metabolites.
Selective iNOS inhibitors and low doses of non-selective NOS inhibitors have been
proved beneficial in sepsis whereas high doses of non-selective inhibitors have proved
detrimental effects during sepsis (327-330). Selective iNOS inhibition has decreased hypotension
in septic shock animals. NO synthesis inhibitors have been shown to improve hemodynamic
variables and survival in several animal models of septic shock. In contrast, iNOS selective
inhibitor has reduced hypotension in rats but could not reduce mortality following sepsis.
Moreover, in sepsis induced acute kidney injury iNOS derived NO and peroxynitrite has played
significant role in renal injury. Therefore, selective inhibition of iNOS has improved sepsis
induced kidney injury.
In addition to this many animal studies has reported the benefits of selective inhibition as
compared to non-selective inhibition of iNOS in improving survival in sepsis induced renal
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disease. A recent study using mice with iNOS deleted gene has confirmed that NO can also exert
anti-inflammatory effects in the intestinal mucosa (335). In contrast, iNOS knockout mice
developed more severe intestinal inflammation and increased perivascular leukocyte recruitment
in a model of acetic acid colitis. In addition, some literature reported that iNOS knockout mice
have been shown resistance to mortality while some studies have shown decreased defence
against bacteria.
iNOS-derived NO contributes to production of cytokines and chemokines under septic
conditions (334). In contrast, iNOS deficiency has reduced brain protein levels of the cytokines
TNF-a, IL-1beta and IL-6 and brain mRNA levels of 2 major chemokines (MIP-1a and MIP-2)
in pneumococcal meningitis.
Coagulopathy is important feature in sepsis which is also associated with endothelial
activation. It has been documented that selective inhibition of iNOS by L-NIL has prevented
increased plasma nitrate/nitrite and isoprostanes concentrations, protected hypotension and
acidosis, inhibited raised plasma vWF and TAT (thrombin anti-thrombin complexes), prevented
decreased t-PA activity in porcine model of sepsis. However, selective inhibition of iNOS could
not reduce PAI-1 levels and increase platelet count. Thus, iNOS beneficial and detrimental
effects are still controversial (336; 336; 337).
During sepsis or septic shock, prostanoids, derived from inducible isoform of
cyclooxygenase-2 (COX-2) are increased. It has been stated that iNOS inhibition has played a
significant role in reduction of COX-2 and therefore prostanoids under septic conditions.
Contrary to this, it has been published that prostanoids like prostacyclin (PGI2) and
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prostaglandin E2 has increased iNOS in cultured cells. Interestingly, thromboxane A2
(vasoconstrictor) plays a protective role by suppressing iNOS derived NO in mice when treated
with thromboxane A2 receptor agonist, U-46619 under septic conditions.
It is already been documented that neither nNOS nor iNOS is completely responsible for
the morbidity and mortality of septic mice. Recently, researchers proposed the idea of inhibiting
both iNOS and nNOS to see the effect in septic animals and in ALI models. In sheep model of
ALI, the combination of early nNOS and delayed iNOS selective pharmacological inhibition
showed reduction in the degree of airway obstruction and improved pulmonary gas exchange,
VEGF, 3- nitrotyrosine, poly (ADP ribose) in pulmonary tissue (325; 326). In mice model of
sepsis induced lung injury, non-selective NOS inhibition has reduced VEGF expression whereas,
combined deletion of nNOS and iNOS genes has reduced VEGF and pulmonary edema. By
contrast, non-selective NOS inhibition has increased mortality in septic mice by showing no
effect on oxidative and nitrosative stress markers in lung. Whereas, deletion of both nNOS- and
iNOS-gene has significantly decreased oxidative and nitrosative stress markers, but could not
improve survival. These studies suggested that combined deletion of iNOS and nNOS has
improved sepsis and ALI but still could not reduce mortility (325; 326). Interestingly, the idea of
simultaneous selective inhibition of nNOS and iNOS showed beneficial results in a sheep model
of burn and smoke induced acute respiratory distress syndrome by inhibiting increased lymph
and plasma nitrate/nitrite levels, pulmonary shunting, ventilatory pressures, lung lymph flow,
and wet/dry weight ratio and significantly improve PaO2/FiO2 ratio. In addition, the idea of
selective inhibition of nNOS or iNOS at different time points striked researcher’s mind when
they found that nNOS inhibition at 4 h has improved survival and significantly attenuated
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contents of lung nitrite/nitrate and liver malondialdehyde and iNOS blockade at 8 hours has
decreased liver malondialdehyde (338). In short, simultaneous selective inhibition of nNOS and
iNOS or selective inhibition of NOS isoforms at appropriate time points can be beneficial
therapeutics for the treatment of sepsis or ALI/ARDS.

D.3.2 Role of NO in ALI/ARDS

Increased NO production is a key feature of ALI. It has been found that increased levels
of NO are generated by iNOS during ALI/ARDS in patients and in animal models of ALI. At
cellular level various studies reported augmentation of macrophage or neutrophil NO after septic
stimulation. Moreover, iNOS derived NO modulate cytokines and chemokines during ALI. This
suggests NO can increase or decrease various cytokines. NO also regulate gene expression or
protein expression. It regulates or activates NF-kappa B activity. NO has been shown to
modulate inflammatory condition through inhibition of iNOS expression induced by cytokines
such as IL-1 beta via inhibition of NF-Kappa-B and IKB-alpha in endothelial cells and VSMCs
(331; 339; 339). Mechanisms of iNOS derived NO in pathophysiology of ALI are still under
debate.
Reactive nitrogen species such as NO, peroxynitrite (ONOO-) and nitrogen dioxide (NO2)
are vital contributors towards tissue injury. However, NO readily reacts with thiol groups and
with molecular oxygen or superoxide to form ONOO-, which results in DNA and membrane
damage by causing peroxidation of membrane phospholipids and nitration of tyrosine residues
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and forms 3 nitro tyrosine and this disrupts endothelial cytoskeleton and cause protein leak.
Increased levels of NO, NO metabolites nitrates, nitrites are found in human and animals BALF
and serum in sepsis, severe sepsis or sepsis induced lung injury (318; 329).
NO is elevated not only in lung during ALI but various clinical studies have shown
elevated urine NO or NO/Creatinine levels during early ALI days also associated with use of low
tidal volume strategy. It has been stated that increased endogenous NO production may be
beneficial during ALI regardless of the fact that higher NO levels are the result of less severe
endothelial epithelial damage.
Inhaled NO (iNO) has generated keen interest in many clinical trials to improve lung
injury. Inhaled NO has reduced transvascular albumin leak in patients with acute respiratory
distress syndrome (ARDS). By contrast, some studies have documented that inhaled NO was
associated with small improvements in the ratio of partial pressure of oxygen to fraction of
inspired oxygen and the oxygenation index but this was short lived and disappeared after 24-48
hours. Therefore, inhaled NO therapy is not recommended as routine treatment for ALI/ARDS,
but can reduce refractory hypoxemia on an individual case basis due to reduction in
intrapulmonary shunting that is due to lack of inadequate blood oxygenation.
NO has been shown to be involved in various cell-cell interactions and injury models in
the lung, and is produced by alveolar epithelial cells, alveolar macrophages, and endothelial cells
of the lung. Previous studies have shown that NO can protect type II pneumocytes from stretch
injury. NO is most important vasodilator in circulation which allows for increased perfusion of
tissues, improved ventilation-to-perfusion matching, and ameliorated oxygenation. Higher NO
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levels could help prevent further tissue damage by improving oxygen and nutrition delivery to
the tissue
iNOS derived NO has shown detrimental and beneficial effects in sepsis or septic ALI
animal models and in human patients. Moreover, iNOS derived NO modulate cytokines and
chemokines during ALI. This suggests NO can increase or decrease various cytokines. NO also
regulate gene expression or protein expression. It regulates NF-kappa B activity. Our lab has
reported reduced protein leak in iNOS knockout mice after septic stimulation (69). In contrast,
many has shown increased protein leak after septic stimulation in iNOS deficient mice. We have
also assessed the role of iNOS derived NO in neutrophil migration during sepsis induced lung
injury model. In our CLP model of acute lung injury, iNOS knockout mice had reduced
neutrophil sequestration to endothelium and increased neutrophil migration as compared to wild
type mice (341). We have also shown cell source specific effects of iNOS derived NO during
ALI. Our lab has shown it is only inflammatory cells (neutrophils and macrophages) iNOS that
contributed to increased protein leak during sepsis induced ALI model (342). Recently we have
shown by using reciprocal BM neutrophils depleted/reconstituted with neutrophil iNOS+/+
chimeric mice that septic ALI is dependent on neutrophil iNOS in vivo (340). Many ongoing and
further researches will be helpful in exploring the mechanism of iNOS derived NO in
pathophysiology of ALI.
Like sepsis, iNOS derived NO and iNOS gene expression itself has been contributed to
variety of diseases like ALI/ARDS. Still the pathophysiology of disease is in debate. iNOS in
ALI has shown both beneficial and detrimental effects. Similarly, iNOS-/- animals has
significantly increased or decreased protein leak during sepsis induced ALI. Some has reported
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that iNOS -/- mice after LPS treatment have increased protein leak while others have shown that
selective inhibition of iNOS has prevented leak in rats following sepsis. Similarly, in our lab,
iNOS derived NO in mice has increased protein leak, increased neutrophil sequestration and
reduced migration after CLP. However, iNOS-/- mice has shown reduction in protein leak,
neutrophil sequestration but increased neutrophil migration in CLP model of ALI (341).
iNOS plays an important role in disrupting cellular junctional proteins. As mentioned
earlier that disrupted F actin formation has potentiated LPS induced iNOS expression. Moreover,
iNOS induction followed by cytokines has relocated VE-cadherin to the site of leak. It has been
stated that LPS mediates protein leak / endothelial barrier dysfunction through various pathways.
In animal model of ALI, LIMK1 which is activated by RhoA/Rho kinase pathway is involved in
RhoA-dependent disruption of endothelial barrier function. Inhibition of LIMK1 by using
LIMK-/- animals has reduced protein leak and neutrophil influx in lungs. In other animal models
of sepsis induced ALI, fusadil (specific ROCK inhibitor) reduces protein leak and leukocyte
adhesion by reducing iNOS in endothelial cells and increasing eNOS. This suggests that iNOS
expression is also altered when Rho is down-regulated due to changes in actin cytoskeleton
structure. Disruption of cytoskeletal structure is also associated with dislocation but not
expression of E-selectin after TNF alpha treatment. Therefore, it modulates neutrophil
attachment under septic conditions. Interestingly, Rho (a small GTP binding protein) is involved
in clustering of E-selectin for neutrophil adhesion. Recently, another signaling pathway class 1,
PI3K contributed to E-selectin dislodgement by cytoskeleton disruption under septic conditions.
iNOS, iNOS derived NO, ROS and RNS has played a significant role in endothelial
activation and dysfunction in sepsis induced lung injury. Moreover, iNOS has been played an
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important role in upregulation of endothelial E-selectin in CLP induced ALI animal models. In
contrast, some has reported no effect of iNOS in endothelial activation following sepsis. In ALI,
NADPH oxidase has played a significant role in promoting lung injury or edema formation. In
addition to this, NADPH oxidase derived from neutrophils contributed to upregulation of
endothelial NFkB dependent ICAM-1 expression under septic conditions. Interestingly, PI3K has
shown to be involved in regulation of ICAM-1 and E-selection through NFkB signaling.
Therefore, deletion of p110γ blocked TNFα-activated ROS generation, NF-κB activation and
reduced MLVEC ICAM-1 and E-selectin expression in mice. Consequently, neutrophils
adherence to endothelial cells is failed.
iNOS and iNOS derived NO also contribute to surfactant disruption during ALI. An
inverse relationship between exogenous natural surfactants (beractant, calfactant or colfosceril)
and surfactant phospholipid (dipalmitoyl phosphatidylcholine, DPPC) and NO, iNOS and
proinflammatory cytokines production in AMs has been proposed. This suggests that antiinflammatory therapies can improve surfactant function in NRDS (neonatal respiratory distress
syndrome).
During ALI, Increased NO synthesis is associated with increased plasma nitrogen oxide
species (NOS) concentration, which was associated with increased microvascular permeability
and pulmonary edema. It has been documented that the combined NOS inhibitor and ONOOblocker mercaptoethylguanidine prevented these effects when administered 1 h after the burn and
smoke injury in animals. Superselective iNOS synthesis (dimerization) inhibitor BBS-2 was
shown to improve pulmonary gas exchange, lung compliance, and airway obstruction and
decreased tracheal blood flow, lung lymph flow, and capillary leakage in another animal model
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of ALI . Some studies have shown that this effect is not due to differences in hydrostatic pressure
but due to peroxynitrite inhibition.
To date, iNOS has been expressed by all almost all cell kinds. Therefore, in our lab we
assessed the role of cell source specific effects of iNOS and iNOS derived NO in sepsis induced
lung injury. As such, we reported that parenchymal (endothelial and epithelial cells) iNOS does
not contribute to protein leak under septic conditions but inflammatory cell (neutrophils and
macrophages) contributed to enhanced protein leak post septic stimulation (342). Our research
did not end here but we also determined the role of inflammatory cell ROS production in protein
leak formation under septic conditions. We have reported that parenchymal ROS and RNS
(peroxynitrite) could not affect protein leak but instead inflammatory cells ROS from NADPH
oxidase and peroxynitrite contributed to protein leak post septic treatment (344).
The role of iNOS in ALI/ARDS is still uncertain with respect to reduction in mortality.
Current research focuses on inhibition of all NOS isoforms or combination of NOS isoforms
inhibition during ALI models. Many ongoing and future studies on the role all NOS isoforms in
ALI/ARDS will be helpful in patient’s survival. My research focused on role of iNOS in
endothelial activation in support of previous evidences provided by our lab.

D.4 Cell source specific effects of NO
D.4.1 Endothelial cells
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Endothelium derived nitric oxide is a potent vasodilator in the vasculature. Nitric oxide
restricts platelet aggregation, leucocyte migration, and cellular adhesion to the endothelium, and
reduces vascular smooth muscle cell proliferation and migration. Moreover, nitric oxide can
suppress activation and endothelial adhesion molecules, and influence production of superoxide
anion. NO derived from constitutive endothelial nitric oxide synthase eNOS and nNOS have
downregulated P-selectin, E-selectin, ICAM-1 VCAM-1 and as a result there is decreased
platelet and leukocyte adhesion during sepsis (210; 211; 302). During early phase of endotoxin
administration, NO produced by eNOS plays a cytoprotective role of NO in lungs. Loss of
endothelium derived nitric oxide would promote vasoconstriction in vasculature. High
concentrations of NO stimulate apoptosis in endothelial cells and cause cell detachment also
called anoikis. Anoikis is initiated by the action of NO. Therefore, NO interferes with focal
adhesion kinase tyrosine phosphorylation and restricts endothelial cell adhesion, spreading and
formation of focal adhesions. In contrast, low concentrations of NO induce anti-apoptotic effect
in endothelial cells through activation of sGC leading to the formation of cGMP.
Nitric oxide (NO) reacts with superoxide anion and forms peroxynitrite which results in
DNA and membrane damage by causing peroxidation of membrane phospholipids and nitration
of tyrosine residues and forms 3-nitro tyrosine and this disrupts endothelial cytoskeleton and
cause protein leak.
Recently, endothelial nNOS pharmacological inhibition (using L-NPA) or siRNA further
increased cytokine-mediated up-regulation of VCAM-1 and proinflammatory cytokines, as well
as increased leukocyte recruitment.
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D.4.2 Neutrophils

Nitric oxide (NO) is a major contributor in neutrophil dysfunction in sepsis. However,
NO synthesis inhibition in sepsis resulted in increased neutrophil death despite restoring
neutrophil migration. TLR activation in human neutrophils leads to decreased chemotaxis due to
chemotactic receptor internalization and increased G protein-coupled receptor kinase 2
expression through involvement of NO-sGC-protein kinase G. Similarly, it has been documented
that NO and ONOO- downregulate neutrophil migration by decreasing adhesion and migration.
In addition, over production of NO induced by Toll like activation attenuates CXCR2 in
circulating neutrophils which correlates impaired neutrophil migration in sepsis.
iNOS derived NO has been involved in pathophysiology of many diseases including ALI/ARDS.
It has shown both beneficial as well as detrimental effects. Our lab has reported reduced protein
leak in iNOS knockout mice after septic stimulation (69). In contrast, many has shown increased
protein leak after septic stimulation in iNOS deficient mice. We have also assessed the role of
iNOS derived NO in neutrophil migration during sepsis induced lung injury model. In our model
of CLP induced acute lung injury, iNOS knockout mice had reduced neutrophil sequestration to
endothelium and increased neutrophil migration as compared to wild type mice (341). We have
also shown cell source specific effects of iNOS derived NO during ALI. Our lab has shown it is
only inflammatory cells (neutrophils and macrophages) iNOS that contributed to increased
protein leak and oxidant stress during sepsis induced ALI model without contribution of
parenchymal iNOS (342). Moreover, we have shown neutrophil ONOO- contributes to transendothelial protein leak in septic ALI (343).
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D.4.3 Macrophages

Alveolar macrophage iNOS derived NO contributes to production of cytokines and
chemokines by alveolar macrophages. However, some studies showed that NO reduces
production of cytokines in alveolar macrophages. Moreover, iNOS derived NO produced by
alveolar macrophages has increased trans-endothelial protein leak under septic conditions. In
addition to this, alveolar macrophage NADPH derived ROS has caused protein oxidation and
lipid peroxidation of PMVEC under septic conditions. Scavenging AM iNOS derived NO and
AM NADPH derived ROS resulted in reduction of PMVEC injury under septic conditions (344).
This suggests alveolar macrophages contribute to extent of septic lung injury.
SECTION E
E. RATIONALE OF STUDIES

The exact role of iNOS derived NO is uncertain in the pathogenesis of sepsis and sepsisinduced lung injury. Studies have shown iNOS-derived NO has beneficial as well as detrimental
effects in septic ALI. Indeed, iNOS inhibition or genetic deletion of iNOS can improve the
degree of lung injury in many models, but does not necessarily improve mortality in animal
models of sepsis and ALI. Our lab has reported iNOS contributes to increased pulmonary protein
leak and oxidant stress in septic mice and in isolated PMVEC. Moreover, we have also
determined the role of iNOS derived NO in neutrophil migration during sepsis induced lung
injury. In our CLP induced septic ALI, iNOS knockout mice had reduced neutrophil
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sequestration to endothelium and increased neutrophil migration as compared to wild type mice.
Moreover, we have pursued the idea of cell-source specific effects of iNOS-derived NO, using
reciprocal BM depleted/reconstituted chimeric mice.

We have found that it is specifically

neutrophil iNOS that mediates septic ALI in vivo, as well as PMVEC septic injury in vitro,
without any apparent contribution of parenchymal (e.g PMVEC) iNOS during septic ALI.
However, the mechanism of neutrophil iNOS-dependent pulmonary microvascular endothelial
cell (PMVEC) injury is not known. Therefore, we assessed septic PMVEC activation in vitro,
and defined the specific role of neutrophils in septic PMVEC activation, and the selective effects
of PMVEC vs neutrophil iNOS in septic PMVEC activation.
E.1

Hypotheses

1. Endothelial iNOS mediates PMVEC activation under septic conditions in vitro
2. Neutrophil iNOS mediates PMVEC activation under septic conditions in vitro
E.2

Objectives

1. To assess the role of endothelial iNOS in PMVEC activation under septic conditions.
a. To characterize PMVEC cell activation under septic conditions in vitro
b. To determine the effect of endothelial iNOS on PMVEC cell activation under septic
conditions in vitro

2. To assess the role of neutrophil iNOS in endothelial cell activation under septic conditions.
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a. To characterize neutrophil activation under septic conditions in vitro
b. To determine the effect of neutrophils on endothelial activation under septic conditions in
vitro
c. To determine the effect of neutrophil iNOS on endothelial cell activation under septic
conditions in vitro

CHAPTER 2: MATERIALS & METHODS
2.1

Animal Preparation
Male C57BL6 iNOS+/+ and iNOS-/- mice (6-8 weeks) were purchased (Jackson

Laboratories, Bar Harbour, Maine, USA) and used for isolation of PMVEC and bone marrow
PMN. All animals’ experimental protocols were approved by the Animal Care and Use
Committee of the University of Western Ontario, and were carried out under supervision of a
veterinarian.

2.2

PMVEC isolation and culture
Murine PMVEC isolation and culture techniques are currently routinely being performed

in our laboratory, as previously described (Razavi et al; 2004). PMVEC were isolated from
subpleural lungs by finely chopping lung tissue, digesting with collagenase (0.2 % in PBS or
DMEM for 30-45 mins at 37oC, time), and filtered through 70 um mesh. Cell suspension was
then incubated with magnetic microbeads bonded to anti-PECAM-antibodies (1.15 -1.5 dilution
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for 1 hr at 4oC). Magnetically-isolated primary PMVEC in culture were grown to 90%
confluence in 2% gelatin-coated flasks, during regular purification every 1-2 days by physical
removal of non-PMVEC cells, which yields PMVEC homogeneity >99% (Razavi et al; 2004).
When cells were grown confluent, they were sorted with FACS by Dil-acetylated LDL uptake.
The cells were then cultured in DMEM (Sigma-Aldrich) supplemented with 1%
streptomycin/penicillin (Sigma-Aldrich, city, state), 50 ug/ml endothelial cell growth supplement
ECGS, 20mM HEPES buffer (Sigma-Aldrich) and 20% FCS (Gibco, London, ON). PMVEC
were maintained in culture conditions (humidified 5% CO2 in incubator at 37oC) and used for
experiments between passages 4 and 8.

2.3

FACS Analysis of PMVEC activation
For in vitro PMVEC activation analysis, cultured PMVECs were treated with LPS 1000

ng/ml (Escherichia coli 0111:B4; Sigma) or cytomix 10 ng/ml (equimolar mixture of cytokines
TNF-α, IL-1β and INF-γ) for t= 1, 2, 4, 8, 12 hrs for analysis of E-selectin expression and t= 2, 4,
8, 12 hrs for analysis of PAI-1 expression in PMVEC. Following trypsinization, PMVEC were
suspended in FACS buffer and were incubated with flourochrome (PE or FITC) conjugated
antibodies against E-selectin (BD pharmingen, Mississauga, ON, Canada), PAI-1 (Innovativeresearch, MI, USA), and PECAM-1 (Biolegend, Burlington, ON, Canada) or with isotype control
antibodies at a concentration of 5 ug/mL or 10ug/ml and analysed by FACS. Cultured PMVECs
treated with medium only served as control. To ensure no contamination of other cells, PECAM1 expression on PMVEC surface was detected which was gated based on FACS forward scatter
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(FSC) and all PECAM-1 positive cells were served as control. The mean fluorescence intensity
(MFI) ratio was normalized to respective isotype control antibody MFI by dividing MFI of Eselectin or PAI-1 stained cells by Isotype stained cells. 10,000 cells per sample were collected
and analyzed with FACS using 488 nm argon laser.
To assess the role of endothelial iNOS in PMVEC activation, PMVEC from iNOS+/+
and iNOS-/- mice were isolated and assessed for E-selectin and PAI-1 upregulation after septic
(LPS, cytomix) stimulation. Moreover, in order to assess the effects of PMVEC iNOS on basal
E-selectin expression, PMVEC isolated from iNOS+/+ mice were pretreated for 24 hrs with
either the non-selective NOS inhibitor L-NG-nitroarginine methyl ester (L-NAME; 100uM)
(Cayman chemical, Ann Arbor, Michigan), or the iNOS selective inhibitor N-(3aminomethylbenzyl acetamide (1400W; 100uM) (Cayman chemical), followed by FACS
analysis of basal E-selectin expression.

2.4

PMN isolation and co-culture with PMVEC
Bone marrow (BM) PMN were isolated from iNOS+/+ and iNOS-/- mice femur, tibia

and fibula bones as previously reported by our laboratory (Razavi et al; 2004). BM PMNs were
isolated by three step percoll gradient density centrifugation. Following centrifugation, the BM
suspension was separated in 5 bands. We carefully removed top two layers containing plasma
and monocytes and the band containing PMNs was carefully isolated and RBCs were lysed by
using d.d H2O or NH4CL based lysis method for 5 mins. PMNs were counted by
haemocytometer and almost 6-15 million PMNs were isolated from each iNOS+/+ or iNOS-/76

mice bone marrows. PMNs were confirmed with Gr-1 staining. PMNs were then incubated with
control medium or septic stimulation.
To assess the potential effects of the presence of PMN and specifically PMN iNOS on
PMVEC activation, PMN-PMVEC co-cultures were treated with septic stimulation vs. control
medium, prior to FACS assessment of E-selectin or PAI-1 expression in PMVEC. 106 PMVEC
were grown to 90% - 100% confluence and 10x106 PMN were applied on the apical surface of
PMVEC, which mimics the in vivo condition as the apical PMVEC surface is exposed to blood
elements in the lumen of the capillary.
Prior to PMN-PMVEC co-culture, BM PMNs were pre-treated with LPS (100ng/ml) or
cytomix (10ng/ml) for 4 hours (37 C, 5% CO2). To assess the potential effects of PMN on
PMVEC E-selectin expression, PMN and PMVEC were co-cultured and further stimulated with
LPS or cytomix for 2 hrs prior to assessment of PMVEC E-selectin expression. To analyse the
potential effects of PMN presence on PMVEC PAI-1 expression, PMN and PMVEC were cocultured for 4 hrs under LPS stimulation or 2 hrs during cytomix stimulation prior to assessment
of PAI-1 expression by FACS.
To analyze the role of PMN iNOS in PMVEC activation, PMN isolated from iNOS+/+
vs. iNOS-/- mice bone marrow (BM) were co-cultured with iNOS+/+ PMVEC under septic
(LPS, cytomix) vs. non-septic control conditions. E-selectin and PAI-1 expression were then
analyzed by FACS.
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2.5

RT-PCR analysis
To analyze the effect of PMVEC iNOS on PAI-1 mRNA in PMVEC, RT-PCR analysis

was performed. The potential effect of presence of iNOS+/+ vs. iNOS-/- PMN on PAI-1 mRNA
in iNOS+/+ PMVEC was also considered. Trizol (Invitrogen, Burlington, ON) according to the
manufacturer's directions was used to extract mRNA from cells. RNA was treated with DNASE
I (Sigma-Aldrich) followed by reverse transcription using Superscript II reverse transcriptase
(Invitrogen). Quantitative real time PCR (qPCR) was used to determine the mRNA expression
levels of PAI-1 (primers: forward 5'-GACAGCACTGTCAGGGTCCATAG-3' and reverse 5'GCGGTCCTCCTTCACAAAGCTC-3')

in

the

cells.

β-actin

(primers:

forward

5'-

TCGTGGGCCGCTCTAGGCACCA-3' and reverse 5'-GTTGGCCTTAGGGTTCAGGGGGG3') was used as reference gene. The qPCR was carried out using Quantifast SYBR Green master
mix (Qiagen, Mississauga, ON) on a Mini-opticon cycler (Bio-Rad, Mississauga, ON). We
followed the following cycling protocol: 95°C for 5 minutes followed by 40 cycles of 95°C for
10s, 60°C for 30 s and 80°C for 30s. SYBR green fluorescence was acquired at 80°C in each
amplification cycle. A melt curve was generated starting at 60°C taking measurements every
0.2°C until 95°C was reached.
2.6

Effect of presence and type of sub cellular matrix on PMVEC basal E-selectin expression

PMVEC are usually cultured on 1% gelatin. The potential effect of the type of matrix
(gelatin vs. matrigel) or the absence of matrix on PMVEC E-selectin expression was assessed.
To achieve this, 1ml of matrigel (Beckton Dickinson) at a dilution of 1:8 in ice cold H2O was
used to coat wells in a 6-well plate, and 500ul of liquid was aspirated, and the wells allowed to
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air dry for 1 hour at room temperature (Martin et al; 1999). 1 ml of 1% gelatin was used to coat
the wells and then aspirated. Wells were then rehydrated with 500 ul of medium, prior to plating
of PMVEC, culture, and FACS analysis.
2.7

Sample Size and statistical analysis

One way ANOVA was used to analyze differences across multiple groups or across
multiple time points, followed by post hoc two sample Dunnett’s t test and Bonferroni correction
for individual comparisons. Statistical significance was accepted when P<0.05.
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CHAPTER 3:
CHAPTER 3: RESULTS
3.1

Analysis of PMVEC activation by FACS

We first established the ability to reproducibly assess PMVEC surface expression of Eselectin and plasminogen activator inhibitor-1 (PAI-1) by FACS. Control staining of cells with
isotype antibodies for E-selectin and PAI-1 were used. The mean fluorescence intensity (MFI)
for E-selectin and PAI-1 for all in vitro experiments were each normalized by dividing by the
MFI of the respective isotype-control antibodies. Under basal, unstimulated conditions, wildtype PMVEC expressed low levels of E-selectin, compared to a negligible signal with isotypecontrol antibody. PMVEC E-selectin expression was markedly increased following LPS
treatment (Figure 3.1). Similarly, wild-type PMVEC expressed very low levels of PAI-1 under
basal conditions, which was enhanced following LPS stimulation (Figure 3.2). Based on this
analysis we can reliably measure E-selectin and PAI-1 expression in PMVEC by FACS.
We next assessed the potential effects of the cultured PMVEC dissociation method on
PMVEC cell surface E-selectin or PAI-1 expression, by comparing the effects of EDTA vs.
trypsin. Following either trypsinization or non-enzymatic/EDTA harvest, PMVEC had similar
levels of basal E-selectin expression and PAI-1 expression (Figure 3.3). Following
trypsinization, E-selectin expression septic upregulation in PMVEC was observed. Although
septic E-selectin also appeared to be upregulated in PMVEC released by EDTA harvest, but the
MFI of isotype antibody varied a lot following EDTA cell dissociation method suggested high
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non-specific binding and giving high non-specific fluorescence. In contrast, the septic increase in
PAI-1 was only detectable using trypsinization method. As such, trypsinization was used as the
PMVEC dissociation method for all subsequent experiments.

3.2

Effects of PMVEC iNOS on Basal PMVEC E-selectin expression

Next, we analyzed the effect of endothelial iNOS on PMVEC E-selectin expression by
comparing iNOS+/+ and iNOS-/- PMVEC. Basal, unstimulated E-selectin expression in
iNOS+/+ PMVEC was significantly higher as compared to iNOS-/- PMVEC (isotypenormalized MFI 59±7, n=22 vs. 16±2, n=36, p<0.05). The effect of the presence and
composition of a subcellular matrix on basal E-selectin in iNOS+/+ and iNOS-/- PMVEC under
non-septic conditions was analyzed. Basal E-selectin expression in iNOS+/+ PMVEC was
consistently higher than in iNOS-/- PMVEC when cells were grown in the absence of any
subcellular matrix, or in the presence of either matrigel or gelatin (Figure 3.4). This suggests that
the difference in basal E-selectin expression between iNOS+/+ vs. iNOS-/- PMVEC is not likely
due to the effects of the sub-cellular matrix.
In another approach, we explored the difference between iNOS+/+ and iNOS-/- PMVEC
basal E-selectin through assessment of the effects of NOS inhibitors on iNOS+/+ PMVEC under
non-septic conditions. We assessed the effects of 24-hours treatment of iNOS+/+ PMVEC with
L-NAME, a non-selective NOS inhibitor (100µM) and 1400W, an iNOS selective inhibitor
(100uM) on E-selectin expression. Complete NOS inhibition (L-NAME) or selective iNOS
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inhibition (1400W) had no effect on basal E-selectin in iNOS+/+ PMVEC at 24 hrs (Figure 3.5).
This suggests that the greater basal E-selectin expression in iNOS+/+ PMVEC is not directly
related to the activity of iNOS or ecNOS.
3.3

Effects of PMVEC iNOS on PMVEC E-selectin expression under septic conditions

PMVEC E-selectin expression rapidly increased, peaking at 2 hrs after septic stimulation
(LPS 1000ng/ml) (Figure 3.6). E-selectin expression peaked at a similar level at 2 hrs (MFI
284±38 vs. MFI 257±29, respectively, p=NS) in iNOS+/+ and iNOS-/- PMVEC. The basal
difference in E-selectin expression between iNOS+/+ and iNOS-/-PMVEC persisted at one hour
after LPS treatment. Overall, there was rapid and widespread expression of E-selectin in both
iNOS+/+ and iNOS-/- PMVEC after LPS stimulation: Two hours following LPS treatment,
95.3±1.0% of iNOS+/+ PMVEC expressed E-selectin (p<0.05 vs control medium-treated) and
97.9±0.4% of iNOS-/- PMVEC cells expressed E-selectin (p<0.05 vs control medium-treated).
In a dose-response study, the significant difference in E-selectin expression between iNOS+/+
and iNOS-/- PMVEC under basal conditions was persistent after LPS stimulation, specifically at
low-moderate level doses, but was lost with high dose LPS stimulation (Figure 3.7).
In a cytomix (10ng/ml) stimulation time course study, PMVEC E-selectin expression
rapidly increased, peaking at 2 hrs after stimulation in both iNOS+/+ and iNOS-/- PMVEC
(Figure 3.8). E-selectin expression peaked at a similar level at 2 hrs (MFI 220±22 vs. MFI
256±40, respectively, p=NS) in iNOS+/+ and iNOS-/- PMVEC. The basal difference in Eselectin expression between iNOS+/+ and iNOS-/-PMVEC persisted at one hour after cytomix
treatment. Two hours following cytomix stimulation, 95.4±0.6% of iNOS+/+ PMVEC and
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96.6±0.9% of iNOS-/- PMVEC expressed E-selectin (both p<0.05 vs respective control mediumtreated cells).
The difference in E-selectin basal expression between iNOS+/+ and iNOS-/- PMVEC
was present following low dose cytomix stimulation, but was lost with moderate-high dose
cytomix (Figure 3.9). The dose-response for cytomix was otherwise similar between iNOS+/+
and iNOS-/- PMVEC.
These data confirm that PMVEC iNOS presence itself does not contribute to PMVEC Eselectin expression upregulation after septic stimulation with either LPS or cytomix.
3.4

Effect of PMVEC iNOS on PMVEC PAI-1 expression under septic conditions

We next assessed the role of endothelial iNOS on PAI-1 expression in iNOS+/+ vs. iNOS/- PMVEC before and after septic stimulation. There was no difference in basal, unstimulated
PAI-1 expression in iNOS+/+ vs. iNOS-/- PMVEC (Figure 3.10). In a LPS treatment time course
study, PAI-1 expression in iNOS+/+ and iNOS-/- PMVEC was increased by 4 hrs after LPS
stimulation, and sustained at 8-12 hrs (Figure 3.10). 99.7±0.2% of cells expressed PAI-1 in
iNOS+/+ PMVEC and 97.8±0.4% of cells expressed PAI-1 in iNOS-/-PMVEC post LPS
stimulation at peak of 12 hrs (both p<0.05 vs respective control medium-treated cells). Following
LPS treatment, PAI-1 was dose-dependently increased in both iNOS+/+ and iNOS-/- PMVEC to
a similar extent (Figure 3.11).
In a cytomix treatment time course study, PAI-1 expression in iNOS+/+ and iNOS-/PMVEC was increased by 2 hrs after cytomix stimulation and was then sustained at 4-8 hrs
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(Figure 3.12). 100±0% of cells expressed PAI-1 in iNOS+/+ PMVEC and 100±0% of cells
expressed PAI-1 in iNOS-/-PMVEC after cytomix stimulation at peak of 2 hrs (p<0.05 vs
respective control medium-treated cells).
Similarly, in cytomix dose response studies, PAI-1 was dose-dependently increased in both
iNOS +/+ and iNOS-/- PMVEC to a similar degree (Figure 3.13).
These data suggest that endothelial iNOS does not contribute to PAI-1 expression in
iNOS+/+ or iNOS-/- PMVEC under basal conditions and post-septic stimulation with either LPS
or cytomix.
It has been reported that PAI-1 is transcriptionally induced after septic stimulation but
surface expression of PAI-1 is transient followed by cleavage and release of PAI-1 into the
circulation. In order to verify induction of PMVEC PAI-1 after septic stimulation, we performed
RT-PCR analysis. The effect of endothelial iNOS on PAI-1 mRNA expression/level in iNOS+/+
vs. iNOS-/- PMVEC was analyzed under septic vs. basal/unstimulated conditions. The basal
PAI-1 mRNA expression was similar in iNOS+/+ vs. iNOS-/- PMVEC. Following 4-hrs septic
stimulation (LPS or cytomix), the increases in PAI-1 mRNA levels were also similar in iNOS+/+
and iNOS-/- PMVEC (p<0.01 by ANOVA for each iNOS+/+ and iNOS-/- PMVEC) (Figure
3.14).
Given the absence of any measurable effect of PMVEC iNOS on PMVEC activation under
septic conditions (LPS or cytomix), as reflected by PMVEC surface E-selectin expression or
PAI-1 expression by FACS, or any effect on PMVEC PAI-1 mRNA expression, all subsequent
studies of PMN-PMVEC co-cultures were carried out using only iNOS+/+ PMVEC.
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3.5

Effect of PMN iNOS on PMVEC E-selectin expression in PMVEC under septic conditions

We next defined the roles of PMN presence in PMN-PMVEC co-culture and PMN iNOS
on PMVEC activation (E-selectin and PAI-1 expression) in iNOS+/+ PMVEC under basal,
unstimulated and septic conditions. In all these PMN-PMVEC co-culture studies, we used PMNs
isolated from mouse bone marrow (BM), as they can be obtained in larger numbers than from
blood.
Isolated iNOS+/+ and iNOS-/- mouse bone marrow PMN were first assessed to confirm
activation after septic stimulation. PMN were assessed for presence of CD11b/CD18 (Mac-1
integrins) post septic stimulation vs. unstimulated PMN. There were no differences in basal,
unstimulated CD11b and CD18 expression in iNOS+/+ vs. iNOS-/- PMN (Figure 14A, B).
Following treatment of iNOS+/+ and iNOS-/- PMN with LPS (100 ng/ml) for 4hrs, there were
marked increases in the expression of both CD11b (MFI 505±64 vs. MFI 537±46, respectively,
p<0.001 for each vs. baseline) and CD18 (MFI 157.96±16 vs. MFI 147.63±11, respectively,
p<0.01 for each vs. baseline) without any difference between iNOS+/+ and iNOS-/- PMN. In
contrast, cytomix (1 or 10 ng/ml) for 4 hrs was not associated with upregulation of either CD11b
or CD18 expression in both iNOS+/+ and iNOS-/- PMN (Figure 3.15). PMN activation marker
(CD11b/CD18) MFI was normalized by subtracting MFI of respective isotype stained cells.
We next examined the role of PMN presence and PMN iNOS on E-selectin expression in
iNOS+/+ PMVEC after septic (LPS or cytomix) stimulation. Co-culture of either iNOS+/+ or
iNOS-/- PMN with PMVEC in the absence of septic stimulation, was associated with mildly
enhanced E-selectin expression in iNOS+/+ PMVEC as compared to PMVEC alone (Figure
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3.16). When iNOS+/+ PMN were pre-stimulated with LPS (100ng/ml) for 4 hrs and co-cultured
with PMVEC during further LPS (0.3ng/ml) stimulation for 2 hrs, PMVEC E-selectin expression
was significantly enhanced as compared to both unstimulated PMN/PMVEC co-cultures and
LPS-treated PMVEC alone (Figure 3.16). There was no difference in PMVEC E-selectin
upregulation following LPS treatment of PMN-PMVEC co-cultures using either iNOS+/+ or
iNOS-/- PMN.
Since we used BM PMNs to access the PMN iNOS effect on endothelial activation, the
BM samples required processing to remove other cellular components, e.g. RBC. Thus, isolated
BM cells were treated with NH4Cl buffer to lyse RBCs and obtain purified PMN prior to septic
stimulation and FACS analysis of PMN. It has been reported that NH4Cl can iodinate PMNs
(Philips et al; 1983), which could affect PMN or PMVEC activation, and possibly confound
interpretation of iNOS+/+ vs iNOS-/- PMN differences. Thus, we compared the effects of two
common RBC lysis methods on PMVEC E-selectin upregulation in LPS-treated PMN-PMVEC
co-cultures (Figure 3.17). Following distilled water or NH4Cl-based RBC lysis methods, we
observed similar upregulation of PMVEC E-selectin expression in LPS-treated PMN-PMVEC
co-cultures with either iNOS+/+ or iNOS-/- PMN (Figure 3.17).
In contrast to LPS-treatment of PMN-PMVEC co-cultures which enhanced PMNdependent PMVEC E-selectin expression, cytomix treatment of PMN-PMVEC co-cultures was
not associated with any upregulation of E-selectin expression in iNOS+/+ PMVEC as compared
to cytomix-stimulated iNOS+/+ PMVEC alone (Figure 3.18). Moreover, this lack of
cytomix/PMN response was similar with either iNOS+/+ or iNOS-/- PMN in co-culture with
PMVEC.
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3.6

Effect of PMN iNOS on PMVEC PAI-1 expression under septic stimulation\

We next examined the role of PMN presence and PMN iNOS on PMVEC PAI-1
expression in PMN-PMVEC co-cultures under septic (LPS or cytomix) stimulation. Co-culture
of either iNOS+/+ or iNOS-/- PMN with PMVEC in the absence of septic stimulation was not
associated with any upregulation of PAI-1 expression in iNOS+/+ PMVEC as compared to
PMVEC alone (Figure 3.19, 3.20). When iNOS+/+ PMN were pre-stimulated with LPS
(100ng/ml) for 4 hrs and co-cultured with PMVEC during further LPS (10 ng/ml) stimulation for
4 hrs, PMVEC PAI-1 expression was not enhanced as compared to both unstimulated PMNPMVEC co-cultures and LPS-treated PMVEC alone (Figure 3.19). Similarly, cytomix (1 ng/mL)
treatment for 4 hrs of PMN-PMVEC co-cultures had no obvious stimulatory effect on PMVEC
PAI-1 expression vs. unstimulated PMN-PMVEC co-cultures and cytomix-treated PMVEC
alone for both iNOS+/+ and iNOS-/- PMN (Figure 3.20).
The effect of PMN presence and PMN iNOS on PMVEC PAI-1 mRNA expression in
PMN-PMVEC co-cultures was also analyzed by RT-PCR. LPS or cytomix treated PMNPMVEC co-cultures using either iNOS+/+ vs. iNOS-/- PMN did not demonstrate any
enhancement of PMVEC PAI-1 mRNA expression (Figure 3.21).
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Figure 3.1: Single channel flow cytometric analysis shows induction of E-selectin expression in
iNOS +/+ PMVEC in response to LPS.
PMVEC were treated with LPS (1000ng/mL; red peak) vs. control medium (black peak)
for 4 hrs. PMVEC were stained with monoclonal antibody to E-selectin and PE-conjugated
secondary antibody and analyzed by FACS. Isotype-control antibodies were used for all studies,
but the signal is not shown here.
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Figure 3.2: Single channel flow cytometric analysis shows induction of PAI-1 expression in
iNOS +/+ PMVEC in response to LPS.
PMVEC were treated with LPS (1000ng/mL; white peak) vs. control medium (black
peak) for 4 hrs. PMVEC were stained with polyclonal antibody to PAI-1 or isotype control
antibody (grey peak) and PE-conjugated secondary antibody and analyzed by FACS.
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Figure 3.3: The effect of trypsin and EDTA methods of cell harvest on cell-surface E-selectin
and PAI-1 expression by FACS in iNOS+/+ murine pulmonary microvascular endothelial cell
(PMVEC).
iNOS+/+ PMVEC were treated with cytomix (10ng/mL) vs. control Medium for 2 hrs,
and then harvested by either trypsin or EDTA treatment, and analyzed for PMVEC surface Eselectin or PAI-1 expression by FACS. For each sample, E-selectin and PAI-1 MFI were Isotype
normalized. *, p<0.05 vs. respective Medium, #, p<0.01 vs. cytomix treated PMVEC; N=3 per
group. Data are presented as mean ± SEM.
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Figure 3.4: The effect of the presence of sub-cellular matrix on basal E-selectin expression in
iNOS+/+ vs. iNOS-/- PMVEC.
iNOS+/+ vs. iNOS-/- PMVEC were cultured in the absence of any sub-cellular matrix, or
the presence of Matrigel (1:8 dilution) or Gelatin (1%). N=3 per group. Data are presented as
mean ± SEM.
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Figure 3.5: The effect of inhibition of nitric oxide synthase (NOS) on basal E-selectin expression
in iNOS+/+ PMVEC under non-septic conditions.
iNOS+/+ mPMVEC were treated with the NOS inhibitors L-NAME and 1400W (100uM)
vs. control Medium/DMSO for 24 hrs. N=4 for each group. Data are presented as mean ± SEM.
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Figure 3.6: Time course of LPS (1000 ng/ml) induced E-selectin expression in iNOS+/+ vs.
iNOS-/- PMVEC.
**, p<0.01 and ***, p<0.001 for LPS-treated vs. respective control Medium; #, p<0.001
vs. similarly-treated iNOS+/+ PMVEC; N=4-9 for iNOS+/+ and N=9-17 for iNOS-/- PMVEC.
Data are presented as mean ± SEM.
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Figure 3.7: Dose-dependent effect of LPS on E-selectin expression in iNOS+/+ vs. iNOS-/PMVEC.
iNOS+/+ vs. iNOS-/- mPMVEC were treated with the indicated doses of LPS vs. control
medium for 2 hrs. *, p<0.05 and **, p<0.01 vs. respective Medium, #, p<0.001 vs. Mediumtreated iNOS+/+ PMVEC; N=4-13 per group. Data are presented as mean ± SEM.
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Figure 3.8: Time course of cytomix (10ng/ml) induced E-selectin expression in iNOS+/+ vs.
iNOS-/- PMVEC.
*, p<0.05 and **, p<0.01 vs. respective Medium; ##, p<0.001 vs. medium-treated
iNOS+/+ PMVEC; N=3 per group. Data are presented as mean ± SEM.
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Figure 3.9: Dose-dependent effect of cytomix on E-selectin expression in iNOS+/+ vs. iNOS-/PMVEC.
iNOS+/+ vs. iNOS-/- mPMVEC were treated with the indicated doses of cytomix vs.
control Medium for 2 hrs. *, p<0.05, ***, p<0.001 vs. respective Medium; N=3-5 per group.
Data are presented as mean ± SEM.
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Figure 3.10: Time course of LPS (1000ng/ml) induced PAI-1 expression by FACS in iNOS+/+
vs. iNOS-/- PMVEC.
*, p<0.05 and ***, p<0.001 vs. respective control Medium; N=4-13 for all groups. Data
are presented as mean ± SEM.
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Figure 3.11: Dose-dependent effect of LPS on PAI-1 expression in iNOS+/+ vs. iNOS-/PMVEC.
iNOS+/+ vs. iNOS-/- mPMVEC were treated with the indicated doses of LPS vs. control
Medium for 12 hrs. *, p<0.05, **, p<0.01 and ***, p<0.001 vs. respective control Medium; N=413 for each group. Data are presented as mean ± SEM.
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Figure 3.12: Time course of cytomix (10ng/ml) induced PAI-1 expression in iNOS+/+ vs. iNOS/- PMVEC.
*, p<0.05 and **, p<0.01 vs. respective control Medium; N=3 per group. Data are
presented as mean ± SEM.
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Figure 3.13: Dose-dependent effect of cytomix on PAI-1 expression in iNOS+/+ vs. iNOS-/PMVEC.
iNOS+/+ vs. iNOS-/- mPMVEC were treated with the indicated doses of cytomix vs.
control Medium for 2 hrs. *, p<0.05, **, p<0.01 vs. respective control Medium; N=3-4 per
group. Data are presented as mean ± SEM.
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Figure 3.14: The effect of endothelial iNOS on septic stimulation (Cytomix 10 ng/mL vs. LPS
1000 ng/mL) induced PAI-1 mRNA expression.
PMVEC PAI-1 mRNA transcript levels were quantified by RT-PCR and normalized to βactin. *, p<0.05 and **, p<0.01 vs. respective Medium; N=4-9 per group. The data is represented
as fold change relative to Medium.
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Figure 3.15: The effect of septic stimulation (cytomix vs. LPS) on the activation of iNOS+/+ vs.
iNOS-/- bone-marrow neutrophils (PMN).
iNOS+/+ vs. iNOS-/- PMN were pre-treated with LPS (100ng/ml) vs. cytomix (1 and
10ng/ml) vs. control Medium for 4 hrs, and then PMN CD11b and CD18 expression were
analyzed by FACS. **, p<0.01 and ***, p<0.001 vs. Medium-treated respective PMN; N=3-4
per group.
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Figure 3.16: The effect of iNOS+/+ vs. iNOS-/- BM PMN on PMVEC E-selectin expression
after LPS stimulation.
iNOS+/+ vs. iNOS-/- PMN were pre-treated with LPS (100ng/ml) vs. control Medium
for 4 hrs and then co-cultured with PMVEC for 2 hrs under LPS (0.3ng/ml) stimulation. *,
p<0.05 and **, p<0.01 vs. control medium; §, p<0.05 and §§, p<0.001 vs. respective Mediumtreated PMN/PMVEC co- cultures; N=4 per group. Data are presented as mean ± SEM.

103

Figure 3.17: The effect of different RBC lysis methods on LPS/PMN induced E-selectin
expression in iNOS+/+ PMVEC.
Following percoll gradient method to isolate bone marrow PMN, PMN were treated with
double distilled water (dd H2O) or NH4Cl based RBC lysis buffer. iNOS+/+ vs. iNOS-/- PMN
were pre-treated with LPS (100ng/ml) for 4 hrs and then co-cultured with PMVEC for 2 hrs
under LPS (0.3ng/ml) stimulation. *, p<0.05, **, p<0.01 and ***, p<0.001 vs. Medium; N=3 per
group. Data are presented as mean ± SEM.
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Figure 3.18: The effect of iNOS+/+ vs. iNOS-/- BM PMN on E-selectin expression in iNOS+/+
PMVEC after cytomix stimulation.
iNOS+/+ vs. iNOS-/- PMN were pre-treated with cytomix (1ng/ml) vs. control Medium
for 4 hrs and then co-cultured with PMVEC for 2 hrs under cytomix (0.3ng/ml) stimulation. N=4
per group. Data are presented as mean ± SEM.
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Figure 3.19: The effect of iNOS+/+ vs. iNOS-/- BM PMN on PAI-1 expression in iNOS+/+
PMVEC after LPS stimulation.
iNOS+/+ vs. iNOS-/- PMN were pre-treated with LPS (100ng/ml) vs. control Medium
for 4 hrs and then co-cultured with PMVEC for 4 hrs under LPS (10ng/mL) stimulation. **,
p<0.01 vs. Medium; §, p<0.05 and §§, p<0.01 vs. respective Medium-treated PMN/PMVEC cocultures; N=3-6. Data are presented as mean ± SEM.
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Figure 3.20: The effect of iNOS+/+ vs. iNOS-/- BM PMN on PAI-1 expression in iNOS+/+
PMVEC after cytomix stimulation.
iNOS+/+ vs. iNOS-/- PMN were pre-treated with cytomix (1ng/ml) vs. control Medium
for 4 hrs and then co-cultured with PMVEC for 2 hrs under cytomix (0.3&1ng/ml) stimulation.
§, p<0.05 vs. respective Medium-treated PMN/PMVEC co- cultures; N=3. Data are presented as
mean ± SEM.
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Figure 3.21: The effect of BM PMN iNOS on septic stimulation (Cytomix vs. LPS) induced
PAI-1 mRNA expression in iNOS+/+ PMVEC.
PMVEC PAI-1 mRNA transcript levels were quantified by RT-PCR and normalized to βactin. N=2-3 per group. The data is represented as fold change relative to Medium.
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CHAPTER 4:
CHAPTER 4: DISCUSSION

These studies assessed activation of PMVEC under different septic conditions such as
LPS and cytomix, as reflected by expression of E-selectin and PAI-1. However, PMVEC iNOS
did not affect LPS or cytomix induced PMVEC activation. PMN enhanced septic PMVEC Eselectin expression following LPS treatment, and this endothelial activation was independent of
PMN iNOS. Contrary to this, PMN failed to enhance PMVEC E-selectin expression post
cytomix stimulation. In addition, PMN failed to upregulate PMVEC PAI-1 expression post LPS
or cytomix stimulation. Our data suggest that septic PMVEC activation in isolation or in the
presence of PMN, is independent of both PMVEC and PMN iNOS.
In the pathophysiology of ALI, many cells contribute such as inflammatory cells and
parenchymal cells. Mainly, inflammatory cells such as neutrophils contribute to the initiation of
inflammatory cascade during septic ALI (345-347). Similarly, EC activation and injury are also
important features of sepsis and sepsis-induced lung injury. During activation, EC increase
permeability and exhibit adhesive and procoagulant state (348; 349).
In this study, we focused on 2 common markers of EC activation. Endothelial E-selectin
mediates leukocyte rolling and adhesion to EC during sepsis, whereas endothelial PAI-1
correlates with increased coagulation and fibrin deposition and endothelial injury during sepsis
or septic ALI (350). Indeed, increased endothelial E-selectin and PAI-1 mRNA levels, as well as
protein expression on the cell surface and also as a soluble form after cleavage from membrane
bound receptors are found in plasma of septic patients and in animals model of sepsis or septic
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ALI. Under basal, non-septic conditions, wild-type PMVEC expressed a low-level of E-selectin,
which was significantly lower in iNOS-/- PMVEC. The basal E-selectin expression differences
were not abrogated when iNOS+/+ and iNOS-/- PMVEC were incubated with either nonselective NOS inhibitor, L-NAME or iNOS selective inhibitor, 1400W. This suggests that
difference in iNOS+/+ vs. iNOS-/- PMVEC basal E-selectin expression is not simply due to
iNOS or cNOS activity. Moreover, iNOS+/+ and iNOS-/-PMVEC when cultured on different
subcellular matrix materials, such as matrigel or gelatin, showed the same difference in basal Eselectin expression. This suggests PMVEC basal E-selectin difference is not related to the
subcellular matrix culture condition.
Wild-type PMVEC E-selectin expression was significantly upregulated under septic
conditions, and to a similar extent post LPS or cytomix stimulation. LPS stimulation also
upregulated PMVEC PAI-1 expression at 4 hrs post stimulation of PMVEC. In contrast, cytomix
induced PMVEC PAI-1 expression at 2 hrs post stimulation. This suggests PMVEC behaved
differently when exposed to LPS or cytomix in terms of PMVEC PAI-1 upregulation, different
from the similar patterns of LPS- and cytomix-stimulated PMVEC E-selectin upregulation. Our
results are in agreement with others in terms of EC E-selectin and PAI-1 expression upregulation
under septic conditions, although shown to different degrees in different types of EC (HUVEC
and human PMVEC) (291; 291; 351-353).
4.1 Role of EC iNOS

During sepsis or septic ALI, NO production and iNOS expression are enhanced, which is
believed to increase the degree of vascular and lung injury (354). Our lab has previously shown
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in a model of septic ALI that iNOS deficient mice post CLP has reduced neutrophil
sequestration, protein leak and increased neutrophil migration (355). iNOS is expressed by a
variety of cells including parenchymal and inflammatory cells. Specifically, it has been reported
that endothelial cells express iNOS and produce iNOS derived NO under septic conditions like
LPS via MAPK dependent pathway (356).
In the present study, iNOS+/+ PMVEC E-selectin expression was upregulated to a
similar extent as in iNOS-/- PMVEC post LPS or cytomix treatment regardless of differences in
basal E-selectin expression in iNOS+/+ PMVEC vs. iNOS-/- PMVEC. Moreover, iNOS+/+ or
iNOS-/- PMVEC E-selectin expression followed a similar time course and dose-response,
independent of iNOS, post LPS or cytomix stimulation. This suggests that the very rapid, early
maximum upregulation of PMVEC E-selectin may facilitate a high-degree of neutrophil
adhesion to PMVEC within the first 2 hrs of septic stimulation.
Similarly, there was no difference in PMVEC PAI-1 expression between iNOS+/+
PMVEC vs. iNOS-/- PMVEC at baseline, or following LPS or cytomix stimulation. It has been
recognized that PMVEC PAI-1 contributes to lung vascular permeability during early lung
inflammation. However, at later stages, PAI-1 contributes to resolution of lung inflammation as
disruption of PAI-1 at later stages increased mortality in P. aeruginosa induced pneumonia in
mice (295). In our study, we found sustained elevation of PMVEC PAI-1 expression at 12 hrs,
which also supports the hypothesis that enhanced coagulation occurs in more delayed fashion,
eg. several hours after septic (LPS or cytomix) stimulation.
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In summary, these above findings suggest that PMVEC iNOS does not affect LPS or
cytomix induced endothelial E-selectin or PAI-1 expression. The possibility that endothelial
iNOS may promote endothelial injury or activation under inflammatory (e.g. septic) conditions is
still controversial. Indeed, we found endothelial iNOS does not contribute to endothelial
activation under different septic conditions. Similarly to our findings, Hickey in 2001 found no
difference in lung endothelial E-selectin expression upregulation in iNOS+/+ or iNOS-/- septic
mice following LPS treatment(357). In contrast, Lush found increased lung tissue endothelial Eselectin expression in iNOS+/+ vs. iNOS-/- septic mice following CLP (358). Moreover, in both
of these latter in vivo murine septic studies, there were no differences in basal endothelial Eselectin expression in unstimulated iNOS+/+ or iNOS-/- mice.
We also found that iNOS+/+ PMVEC E-selectin expression was higher than iNOS-/PMVEC, and this difference was not related to the use of different subcellular matrix conditions.
Moreover, NOS inhibitors (both iNOS-selective 1400W and non-selective L-NAME) did not
affect this PMVEC basal E-selectin expression difference between iNOS+/+ and iNOS-/PMVEC. In contrast to our findings, TNF alpha-stimulated PMVEC E-selectin expression was
attenuated with L-NAME or when PMVEC were isolated from eNOS-deficient mice (359). We
speculate that our observed difference could be due to in vitro culture conditions, which may not
reflect in vivo differences, or possibly to other unexpected differences between iNOS+/+ vs
iNOS-/- PMVEC, as a result of genetic absence of iNOS.
NOS can also modulate endothelial PAI-1 expression during septic ALI, although the
effects remain controversial. For example, endogenous NOS activator L-arginine induced PAI-1
antigen in an EC line (EA hy 926) after TNF alpha stimulation, whereas the non-selective NOS
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inhibitor L-NAME reduced EC surface PAI-1 antigen (360). In contrast, others have reported
that GTPase Rac1 dependent ecNOS-derived NO production in EC reduces PAI-1 upregulation
(361). Finally, it was also reported that NO does not contribute to LPS induced PAI-1 expression
in HUVEC (362). These data suggest that the role of NO in EC PAI-1 upregulation under
inflammatory/septic conditions is still uncertain. Therefore we investigated role of EC iNOS in
PMVEC PAI-1 expression and mRNA level upregulation under different septic conditions. Our
results are consistent with Perez Ruiz that showed septic PMVEC PAI-1 upregulation was
independent of EC iNOS after LPS or cytomix stimulation.
4.2 Role of PMN and PMN iNOS

Neutrophils are involved in endothelial activation, injury and apoptosis during sepsis and
septic ALI (357; 363). Furthermore, our lab has shown in mice model of septic ALI, anti-CD18
treatment in mice prior to CLP has significantly reduced pulmonary MPO levels, BAL
neutrophils, protein leak and 8-isoprotane levels (Wang L et al;2012). This suggests neutrophils
contribute importantly in development of septic ALI. In the present study, the presence of PMN
in co-culture with PMVEC synergistically enhanced LPS induced PMVEC E-selectin expression
in a dose-dependent manner. However, this PMN-dependent PMVEC E-selectin induction was
similar between iNOS+/+ and iNOS-/- PMN, and thus septic (LPS) PMN-dependent PMVEC
activation also appears to be independent of PMN iNOS. In contrast, the presence of PMN in coculture with PMVEC under cytomix stimulation did not enhance PMVEC E-selectin expression,
and this was similar between iNOS+/+ PMN and iNOS-/- PMN. These data suggest that there is
differential activation of PMN under different septic conditions, e.g. Cytomix vs LPS, and a
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resulting difference in PMN-dependent PMVEC activation. Importantly, septic PMN-dependent
PMVEC activation, as reflected by E-selectin expression, was independent of both PMVEC and
PMN iNOS.
In contrast to LPS-induced PMN-dependent PMVEC E-selectin upregulation, the
presence of PMN in co-culture with PMVEC under LPS or cytomix treatment did not upregulate
PMVEC PAI-1 expression. Moreover, iNOS+/+ or iNOS-/- PMN with PMVEC could not affect
PMVEC PAI-1 expression post LPS or cytomix stimulation. Similarly, iNOS+/+PMN or iNOS/-PMN did not affect PMVEC PAI-1 mRNA expression after LPS or cytomix treatment.
Among diverse functions of neutrophil during sepsis, many have shown a neutrophil
contribution towards cultured EC activation and injury (363). For example, It has been reported
that PMN when co-cultured with HUVEC post fMLP treatment has increased procoagulant
factors such as TF (364). Similarly, human neutrophils when co-cultured with HUVEC in the
presence of TNF α have shown to upregulate HUVEC E-selectin expression at 24 hrs (365).
During neutrophil activation, there are many potential mechanisms of EC
activation/injury. These include neutrophil-derived cytokines, NO, ROS, and proteases. For
example, neutrophil TNF α has induced endothelial adhesion molecules such as E-selectin, Pselectin, ICAM-1, VCAM-1 whereas, neutrophil IFN-γ gamma has shown to increase ICAM-1 ,
P-selectin, E-selectin and reduce VCAM-1 under shear stress (366).
We had hypothesized that neutrophil iNOS could contribute to endothelial activation
under septic conditions. We have previously shown in septic mice BM-derived neutrophil iNOS
dependent pulmonary microvascular trans-EC protein leak, pulmonary oxidant stress and
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nitrosative stress in vivo, and reduced trans-endothelial migration in vivo and in vitro (69); (355).
Moreover, we found that inflammatory cell (neutrophil) source of iNOS contributes importantly
to trans-human PMVEC albumin leak in vitro, without any contribution of PMVEC iNOS (367).
Recently we have proved by using reciprocal BM neutrophils depleted/reconstituted with
neutrophil iNOS+/+ chimeric mice that septic ALI is dependent on neutrophil iNOS in vivo (70).
In the present study, our results showed that PMN iNOS does not contribute to PMVEC Eselectin or PAI-1 upregulation post LPS or cytomix treatment. There are limited studies in
similar PMVEC, however, the NO donor, SNAP did enhance PMN-induced HUVEC E-selectin
expression (368). This discrepancy may be due to many factors, including interspecies
differences, micro vs macrovascular EC heterogeneity, and type of septic stimulus used.
Other neutrophil mediators likely explain PMVEC activation in the current study.
Neutrophil peptides and proteases such as antimicrobial proteins, elastase, Cathepsin G, and
others have been shown to modulate endothelial integrity and cytoskeleton during septic
conditions. For example, it has been reported that recombinant cationic antimicrobial protein of
molecular weight 37 kDa (CAP37), a neutrophil-derived protein, upregulated the expression of
VCAM-1 and E-selectin in EC (369). In addition, neutrophil proteases contributed to
upregulation of endothelial PAI-1 in sepsis induced liver injury. As it is evident from our results
that under different septic conditions, activation or non-activation of neutrophils did not affect
PAI-1 upregulation. This suggests neutrophils behave differently under different septic
conditions to activate endothelial cells in a manner that can potentiate or fine tune inflammatory
response.
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4.3 Limitations

We appreciate the constraints posed by the use of cytomix to mimic sepsis. The in vitro
model (i.e., cytomix) does not exactly reflects human sepsis but only provides exposure to proinflammatory mediators of sepsis which are involved in pathogenesis of sepsis or septic ALI.
Cytomix has been used extensively to model sepsis in in vitro studies using endothelial and
inflammatory cells, but the exact composition of cytomix is extremely variable (345; 346; 346;
367; 370). Our choice of cytomix components and concentrations was based on preliminary in
vitro data from our lab on PMN-dependent EC injury, characterized by albumin leak.
We only focused on the role of iNOS specifically in PMVEC and PMN, based on our
extensive work in vivo in murine sepsis. Clearly, eNOS could be an important source of NO
which may have some modulatory effects in our model. For example, NO derived from eNOS
has shown to reduce endothelial activation by attenuating P-selectin, E-selectin, ICAM-1,
VCAM-1 levels during sepsis (371). Moreover, NO donors have shown to reduce PMVEC Eselectin expression after TNFα stimulation (291).
Our assessment of PMN-dependent effects under septic conditions depends upon
adequate stimulation of PMN. The lack of PAI-1 response to cytomix suggested that may be
cytomix failed to activate PMN adequately. Indeed, our PMN activation results showed that LPS
significantly upregulated CD11b/CD18 expressions but cytomix failed to upregulate
CD11b/CD18 expressions on PMN. Our results of PMN activation by LPS are consistent with
other literature (372).
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We assessed surface E-selectin by FACS as a marker of PMVEC activation. The surface
E-selectin signal could have been affected by other biologic processes. For example, endothelial
E-selectin is also shed as a soluble E-selectin in plasma or it is clustered by lipid rafts or clathrin
coated pits or internalized by clathrin coated pits (353; 373). However, we clearly found a
significant upregulation of surface E-selectin, suggesting that septic E-selectin shedding does not
necessarily result in reduction in endothelial cell surface E-selectin expression.

4.4 Summary

PMVEC E-selectin and PAI-1 are activated under different septic conditions and this
upregulation is independent of PMVEC iNOS. Neutrophils behave differently to activate
endothelial cells under different septic conditions. PMN can upregulate PMVEC E-selectin
expression post LPS in a dose dependent manner but not during cytomix treatment, and PMNdependent PMVEC activation was independent of PMN iNOS. Furthermore, PMN did not
upregulate PMVEC PAI-1 expression post LPS or cytomix stimulation. Moreover, PMN iNOS
did not affect PMVEC E-selectin or PAI-1 upregulation post LPS or cytomix stimulation. This
study suggests that PMN iNOS dependent PMVEC injury does not appear to be mediated
through PMN iNOS dependent PMVEC activation. Therefore, further studies will be required to
further explore potential mechanisms of the PMN iNOS-derived NO role in septic PMVEC
injury.
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CHAPTER 5:
CHAPTER 5: THESIS SUMMARY

5.1

Hypothesis 1 –Pulmonary microvascular endothelial cells (PMVEC) iNOS contributes to
PMVEC activation under septic conditions in vitro.
In these studies, we investigated the role of iNOS in isolated PMVEC activation under

septic conditions. We characterized activation of PMVEC by assessing upregulation of the
adhesion molecule E-selectin and the procoagulant factor PAI-1 under different septic
conditions, specifically LPS and cytomix. To pursue the role of PMVEC iNOS in PMVEC
activation, we isolated, cultured and studied PMVEC from iNOS+/+ and iNOS-/- mice. We
assessed PMVEC basal and septic upregulation of E-selectin and PAI-1 expression by flow
cytometry.
We found iNOS+/+ PMVEC basal E-selectin expression was higher than iNOS-/- PMVEC,
but this difference appeared to not be due to either iNOS or cNOS activity, or to the specific sub
cellular matrix used in PMVEC culture. However, iNOS+/+ or iNOS-/- PMVEC E-selectin
expression is upregulated post LPS or cytomix stimulation. Thus, we found PMVEC iNOS does
not contribute to induction of PMVEC E-selectin expression under septic conditions. Moreover,
PAI-1 from iNOS+/+ or iNOS-/- PMVEC followed similar pattern of upregulation of expression
post LPS or cytomix stimulation vs. control or medium. However, the expression was only
detectable in PMVEC. Our result suggested that PMVEC iNOS does not contribute to PMVEC
PAI-1 expression upregulation under septic conditions. In addition, we also determined the role
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of PMVEC iNOS in PAI-1 mRNA levels post LPS or cytomix stimulation. Our results suggested
that PAI-1 gene expression post septic stimulation vs. control is not PMVEC iNOS dependent.
We conclude PMVEC iNOS does not contribute to PMVEC E-selectin or PAI-1 expression
under basal conditions or following septic stimulation.

5.2

Hypothesis 2 – Bone marrow neutrophil (PMN) iNOS contributes to pulmonary
microvascular endothelial cell activation (PMVEC) under septic conditions in vitro.

In these studies, we assessed one potential mechanism of PMN iNOS-dependent septic
PMVEC injury, by investigating the role of PMN iNOS in PMVEC activation under septic
conditions. We analyzed PMVEC E-selectin and PAI-1 expression by flow cytometry in PMNPMVEC co-cultures in vitro. PMVEC isolated from WT mice were incubated with LPS or
cytomix pretreated PMN isolated from bone marrow of iNOS+/+ and iNOS-/- mice.
We found both iNOS+/+ or iNOS-/- PMN synergistically enhanced PMVEC E-selectin
expression post LPS stimulation in a dose dependent manner. However, PMN iNOS did not
affect PMVEC expression upregulation post LPS stimulation. In contrast, neither PMN nor PMN
iNOS affected PMVEC PAI-1 expression or PAI-1 mRNA level induction post LPS or cytomix
treatment. We next assessed PMN activation after LPS or cytomix stimulation. We assessed
activation of beta 2 integrins (CD11b/CD18) by flow cytometry. Our results showed a dramatic
enhancement of CD11b and CD18 expression post LPS stimulation. In contrast, cytomix could
not increase any of CD11b or CD18 expression. This study suggests that PMNs behave
differently under different septic conditions to activate endothelial cells. However, PMN iNOS
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does not appear to contribute to PMVEC E-selectin or PAI-1 upregulation under septic
conditions. Therefore, we conclude that septic PMN iNOS-dependent PMVEC injury is likely
not mediated through PMN iNOS-dependent PMVEC activation.
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CHAPTER 6: GENERAL DISCUSSION

6.1 Introduction
This thesis assessed the presence of PMVEC activation under different septic conditions in
vitro, assessed the role of PMVEC iNOS in septic PMVEC activation and the specific
involvement of iNOS in both the PMVEC and in co-cultured PMN. PMN behaved differently
with regards to PMVEC activation under different septic conditions. PMN significantly
enhanced PMVEC E-selectin expression in a dose dependent manner after LPS stimulation, and
this PMN-dependent effect was independent of PMN iNOS. PMN had no effect on PMVEC Eselectin expression during cytomix treatment, and did not affect PMVEC PAI-1 upregulation or
mRNA level after LPS or cytomix stimulation. Interestingly, LPS showed a dramatic elevation
of CD11b and CD18 expression in isolated PMN, but cytomix failed to activate PMN.
ALI is characterized by impaired gaseous exchange, diffuse alveolar injury, increased
endothelial injury and permeability and increased neutrophil influx (70; 374; 375). PMVEC are
activated under different septic conditions as shown in our results (chapter 6). We hypothesized
that PMVEC iNOS and PMN iNOS contributes in PMVEC activation as our lab has previously
shown the important contribution PMN iNOS-dependent PMVEC injury under septic conditions
in vivo and in vitro, and septic PMVEC injury was independent of PMVEC iNOS (69).
6.2 Assessment of EC activation
Endothelial cell activation and injury are important features in the development of sepsis
and septic ALI. During activation of endothelial cells, they become highly permeable, pro121

adhesive, and procoagulant. Expression of the EC adhesion molecule, E-selectin, has been
assessed by a number of researchers for its contribution to leukocyte-EC adhesion. E-selectin is
endothelial specific and is a common marker of endothelial activation (376). Procoagulant factor
PAI-1 presence and expression has also been defined in experiments by many researchers.
Although PAI-1 is also expressed by platelets, it can be used as a marker of endothelial
activation (377). In this study, we used flow cytometry to assess EC surface protein expression.
For our in vitro protocol, we used trypsinization as a cell dissociation method prior to analysis of
PMVEC E-selectin or PAI-1 by FACS. Our PMVEC were grown to confluence and then treated
with control medium vs. LPS or cytomix stimulation prior to being assessed by FACS.
6.3 Endothelial iNOS effect on EC activation

Endothelial iNOS is upregulated during sepsis and septic ALI. Moreover, endothelial
iNOS has been shown to contribute to vascular abnormalities during sepsis and impairment of
several lung physiological functions such as regulation of pulmonary vascular tone,
immunocompetence, and neuronal signaling (378). Endothelial iNOS contributed to endothelial
dysfunction of vascular and conduit arteries during endotoxemia (379). Endothelial iNOS has
been shown to contribute to the progression of delayed circulatory failure in septic shock (380).
In previous work from our lab, endothelial iNOS expression did not contribute to septic
ALI in septic mice, or EC injury in vitro (356; 367). In the present study, we investigated the role
of endothelial iNOS in PMVEC septic activation. We found that PMVEC iNOS does not appear
to contribute to LPS or cytomix induced PMVEC E-selectin or PAI-1 expression. Similar to our
findings, Hickey in 2001 found no difference in lung EC E-selectin expression upregulation in
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iNOS+/+ or iNOS-/- septic mice post LPS stimulation (357). In contrast, Lush in 2001 found
increased lung EC E-selectin expression in iNOS+/+ vs. iNOS-/- septic mice post CLP (357;
358). However, the difference in lung EC E-selectin expression in vivo could have been due to
the effects of iNOS in other cells and not specifically in the EC themselves.
In the present study, we found higher iNOS+/+ PMVEC basal E-selectin expression as
compared to iNOS-/- PMVEC. Interestingly, two previous in vivo studies did not find any
difference in basal, unstimulated endothelial E-selectin expression between iNOS+/+ or iNOS-/mice (357; 358). Moreover, it was previously reported that the iNOS-specific inhibitor 1400W
did not modulate PMVEC basal E-selectin expression, however, non-selective NOS inhibition
reduced TNFα-induced E-selectin expression in PMVEC (359). The role of endothelial iNOS in
endothelial activation is still under debate.
6.4 Neutrophil iNOS effect on endothelial activation under septic conditions

Upregulation of neutrophil iNOS contributes importantly to the pathophysiology of sepsis
and especially sepsis-induced ALI. Using bone-marrow transplanted chimeric mice, our lab has
previously shown murine neutrophil iNOS-dependent trans-endothelial pulmonary microvascular
protein leak, pulmonary oxidant stress and nitrosative stress in sepsis in vivo, as well as
neutrophil iNOS-dependent regulation of murine trans-endothelial PMN migration in sepsis
(355);(367). Recently we also definitively showed using reciprocal neutrophil-specific iNOS
chimeras that septic ALI was almost completely dependent on neutrophil iNOS in vivo (70).
Moreover, we found both in murine and human cell culture that neutrophil iNOS contributes
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importantly to trans-EC albumin leak in vitro (367).

These data strongly support an essential

role of neutrophil iNOS in septic lung injury and specifically PMVEC injury.
In the present studies, we investigated the role of neutrophil iNOS in PMVEC activation
under different septic conditions in vitro. We found neutrophils synergistically upregulated
PMVEC E-selectin expression post LPS treatment in a dose dependent manner. However, we
found that neutrophil iNOS does not contribute to septic PMVEC E-selectin upregulation.
Unfortunately, we could not demonstrate PMN-dependent PMVEC activation under
cytomix treatment, nor was there any PMN-dependent effects on septic PMVEC PAI-1
expression. Thus, we also conclude that PMN are differentially activated under different septic
conditions.
6.5 General implications of thesis

Pulmonary microvascular endothelial cells are activated during septic ALI, and this could
influence neutrophil-endothelial interactions, which could contribute to septic endothelial injury.
Activated endothelial cells can also enhance coagulation and microvascular thrombotic events
during septic ALI. PMVEC E-selectin was significantly upregulated post LPS or cytomix
stimulation, which can mimic systemic septic activation of endothelial cells, and results in
enhanced inflammatory cell-EC adhesion. PMVEC showed maximum upregulation of E-selectin
expression at early hours post septic stimulation, which is consistent with observations that
leukocyte and endothelial interactions occur early during sepsis. In contrast, septic PMVEC PAI-
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1 expression was detectable at later timepoints during septic stimulation. This suggests that
thrombotic events may occur later during sepsis or septic ALI.
We also demonstrated that septic PMVEC activation, as reflected by E-selectin and PAI-1
upregulation, is independent of both PMVEC and PMN iNOS. Given previous reports of PMN
iNOS-dependent septic PMVEC injury/dysfunction, our current findings suggest that this PMNdependent injury is not mediated through PMVEC activation. As such, the results of the present
studies suggest that PMN iNOS-dependent septic PMVEC injury may be mediated through other
mechanisms, such as cytoskeleton disruption and/or junctional protein damage.
6.6 Future directions

1. Assessment of the effect of PMN and PMN vs PMVEC iNOS on other markers of EC
activation.
2. Assessment of the possible role of PMN iNOS in septic human PMVEC activation as a
potential mechanism of documented PMN-dependent septic human PMVEC injury in
vitro
3. Assessment of other potential mechanisms of PMN iNOS-dependent septic murine
PMVEC injury/dysfunction, specifically PMVEC cytoskeletal arrangement or
junctional protein disruption under septic conditions
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